








An integrated approach to outcome evaluation: Incorporating Patient 








This thesis is presented for the Degree of 












published by any other person except where due acknowledgement has been
made.












I started my PhD journey because I was afraid. Afraid of not being “good enough” 
and “smart enough”. I felt like a fraud most of the time as an academic. To me PhD 
was not just a journey to become an independent researcher but a path to self- 
discovery and a different way to see the world.  At the start of my PhD, I was asked 
by the Dean of my school at University of Western Sydney, how I saw myself at the 
end of my PhD and I told him I see myself as not being afraid and now I believe I am 
getting there. 
It all started when my good friend Associate Professor Yenna Salamonson 
introduced me to Professor Davidson. It marked the beginning of my PhD journey, 
and more importantly, the beginning of a very rewarding relationship both on a 
personal and professional level with Professor Davidson. She has opened doors I 
never dreamed was for someone like me!  She has nurtured and encouraged me to 
believe and not to be afraid to make mistakes. Thank you for being a wonderful and 
generous supervisor! 
During my PhD I had the privilege of being encouraged and supported by extremely 
talented but giving research leaders. Amongst them, I would especially like to thank 
Professors Henry Krum, Harlan Krumholz and Peter Macdonald. Your insightful 
comments and generous support have sharpened my thinking and understanding. 
To Phil, who always looked out for me and supported me when I felt really unsure, 
thank you. 
To WHICH(?) trial collaborators, thank you for giving me permission to use the data.    
To Sally, Michelle and Tim, thank you for providing interesting discussion on various 
research and sometimes not so research topics.  
To Sabine, thank you for formatting my thesis.   
To my sister and my best friend Connie, for being a surrogate mum to my son Caleb, 
cooking, shopping and being my soundboard as well as reading my chapters, thank 




dedication. Thank you Daniel and Joshua for half- adopting Caleb as your brother 
and son. To mum and dad, thank you for your prayers. Despite the distance I know 
your concern and love have supported me in an amazing way. To my husband 
Ricardo and my son Caleb thank you for your prayers and tolerance. You really were 
the anchor throughout this whole journey. 




Anthology of publications and presentations 
associated with this thesis 
Papers Published 
Chang, S, Newton, PJ., Inglis, SC., Luckett, T, Krum, H, Macdonald, PS, & Davidson, 
PM. Are all outcomes in chronic heart failure rated equally?: an argument for a 
patient-centred approach to outcome assessment? Heart Failure Review. {Epub 
ahead of print] http://dx.doi.org/10.1007/s10741-012-9369-0 (Impact Factor: 
3.200) 
 
Chang, S, Davidson, PM, Newton, PJ, Krum, H, Salamonson, Y, & Macdonald, PS. 
What is the quality of reporting of health related quality of life in chronic heart 
failure clinical trials? International Journal of Cardiology. [Epub ahead of print] 
http://dx.doi.org/10.1016/J.IJCARD.2012.01.019 (Impact Factor: 7.078) 
 
Chang, S, Gholizadeh, L, Salamonson, Y, Digiacomo, M, Betihavas, V, & Davidson, 
PM,. Health span or life span: the role of patient-reported outcomes in informing 
health policy. Health Policy, 2011. 100: p. 96-104. (Impact Factor: 1.383) 
 
Cao, X, Cao, Y, Salamonson, Y, DiGiacomo, M, Chen, Y, Chang, S, Riegel, B, & 
Davidson. PM. Translation and validation of the Chinese version of the Acute 
Coronary Syndrome Response Index (C-ACSRI). International Journal of Nursing 
Studies, 2012. 49:,p. 1277-1290. (Impact Factor: 2.103) 
 
Juntasopeepun, P, Davidson, PM, Chang, S, Suwan, N, Phianmongkhol, Y, & 
Srisomboon, J. Development and psychometric evaluation of the Thai Human 
Papillomavirus Beliefs Scale. Nursing and Health Sciences. 13: p. 475-480. (Impact 
Factor: 0.571) 
 
Gholizadeh, L., Salamonson, Y, Davidson, PM., Parvan, K, Frost, S A., Chang, S, & 
Hare, DL. Cross-cultural validation of the Cardiac Depression Scale in Iran. British 
Journal of Clinical Psychology, 49: p. 517-528. (Impact Factor: 1.697) 
 
van der Sluijs, C., Bensoussan, A. & Chang, S., A randomized placebo-controlled trial 
on the effectiveness of an herbal formula to alleviate menopausal vasomotor 










Salamonson, Y., Weaver, R., Chang, S., Koch, J., Bhathal, R., Khoo, C. & Wilson. I. 
(2012). Learning approaches as predictors of academic performance in first year 
Health and Science students. NETNEP 2012 - The 4th International Nurse Education 
Conference in Baltimore, MD, USA from 17-20 June 2012. 
Chang, S., Newton, P. J., Salamonson, Y., Macdonald, P. & Davidson, P. 
M.(2010).  Health related quality of life assessment in pharmacological clinical trials: 
rigor of measurement and reporting. The14th Annual Scientific meeting of the 
Heart Failure Society of America in San Diego, CA from 12-15 September 2010.  
Chang, S., Rolley, JX., Salamonson, Y., Newton, P. J., & Davidson, P. M. (2010). A 
schemata for comprehensive health service evaluation. The 4th Australasian 
Cardiovascular Nursing College (ACNC) Annual Conference in Brisbane from 12-13 
March 2010. 
Chang, S., Rolley, JX., Salamonson, Y., Newton, PJ., & Davidson, PM. (2009). A 
schemata for comprehensive health service evaluation. 19th Annual Scientific 
Meeting of the Australian Cardiovascular Health and Rehabilitation Association 








Globally individuals and health care systems are facing the burden of chronic illness.  
The impact of the increasing burden of non-communicable diseases is experienced 
by individuals and health care systems. Across the globe health care systems are 
struggling to meet the increasing demands for services within the confines of rising 
costs and needs for accountability.  Beyond costs and treatment allocations, there 
is an increasing mandate to provide care that is patient centred and appropriate to 
the needs of the individual.  The Innovative Care in Chronic Condition (ICCC) 
framework has been successful in driving health care reforms to meet the needs of 
individuals with chronic illness internationally. Deriving metrics that allow 
monitoring of conditions at the level of the patient, provider and health care 
system are of increasing importance.  Comprising this thesis is a series of studies to 
investigate outcomes that includes the patient’s perspective in the evaluation of 
clinical interventions. To achieve this, chronic heart failure, was used as an 
exemplar of a chronic condition. 
Chronic heart failure (CHF) is the final common pathway for many cardiac 
conditions. As a consequence has emerged as a major public health problem and 
represents as an excellent exemplar of living with a chronic illness.  CHF patients 
commonly experience high levels of ill-health, disability and mortality placing a 
heavy burden on health care systems. Hospitalisations are frequent and costly to 
both CHF patients and to society.  People with CHF live with a limited quality of life 
and physical ability and the prognosis for CHF is poor. Given the nature of 
debilitating symptoms, and their potential impact on physical, social and 
psychological aspects of life, patient’s perspective in outcome assessment is 
essential in providing effective care. 
Specifically this study sought to:  
 Examine patient reported outcomes in clinical management and in clinical 
research  
 Investigate patient important outcomes, their utility, relevance and 




 Test composite outcomes model that integrate patient important outcomes 
in clinical trials research  
Patient reported outcomes (PROs) is a strategy to capture the patient perspective 
and experience on their health status.  The use of PROs can be incorporated in 
clinical assessments, monitoring of clinical progress as well as clinical research. 
Despite their frequent use in research, evidence suggests that to date they have 
had a limited influence on clinical practice and policy.  As part of this thesis an 
integrative review was conducted to explore the potential utility of PROs at the 
policy level. By using the ICCC framework, PROs were indeed essential to improve 
the management of CHF at the micro, meso and macro levels of decision making. 
One of the key challenges in using PROs and outcomes important to individuals in 
CHF is limited methodological and reporting quality. This is cited as a reason why 
many clinicians are sceptical of the utility of PROs.  To explore issues in reporting a 
review was conducted on RCTs of pharmacological therapy in CHF that reported 
health related quality of life (HRQoL) as a primary or secondary outcome. Using the 
Minimum Standard Checklist for evaluating the quality of reporting of HRQoL 
outcomes resulted in 26 (19.1%) studies  being considered ‘very limited’ in terms of 
methodological and reporting rigour, and 91 (66.9%) were evaluated as ‘limited’ 
and only 19 (14.0%) studies were considered to be of a ‘probably robust’ quality. In 
fact, the quality of HRQoL reporting has not improved over time. Some of the issues 
identified are limited discussions, methodological shortcomings, and poor HRQoL 
reporting.  This review has underscored the importance of standardising of the 
reporting of HRQoL measures.  
Although capturing the patient’s perspective via PROs is important, they may not be 
the only outcome measures important to patients. Currently, no single CHF 
outcome measure captures all dimensions of the quality of care from the patient’s 
perspective. To identify outcome measures in CHF deemed important to patients, a 
structured literature review was undertaken. The conceptual and methodological 
challenges and opportunities in each outcome measure were identified as 




identified as important to patients but also meaningful and relevant to the provider 
and health care system as well. These outcome measures were proposed as a core 
outcome set that represent the minimum set of outcomes that should be measured 
and reported in CHF.  
A number of composite outcome measures have been developed to capture the 
perspective of the patient, clinician as well as including objective measures of 
health. Three validated composite outcomes, the Packer’s Score, Cleland’s Patient 
Journey and the composite endpoint used in the African American Heart Failure 
Trial (A-HeFT) were examined in a secondary analysis of a prospective, multi-center 
randomized controlled trial of 280 hospitalized CHF patients in the Which Heart 
failure Intervention is most Cost-effective & Consumer Friendly in Reducing 
Hospital Care (WHICH?) Trial in order to assess the comparability and 
interpretability of the measures in a pragmatic clinical trial. Correlation coefficients 
demonstrated substantial associations amongst all three composite endpoints. 
Although there was a considerable agreement across the three measures when 
estimating deteriorating condition, these was less when estimating improvements. 
This thesis has described both the importance and complexity of including outcome 
measures that are meaningful to patients in both the assessment of individuals’ 
needs, testing interventions, monitoring outcomes and assessing process and 
outcome measures at a health systems level. This thesis has also extended the 
discussion and debate around PROs to discuss Patient Important Outcomes, which 
is outcomes that patients notice and for which they would be willing to undergo a 
treatment with associated risk, cost, or inconvenience for it to be the only thing 
that changed. Using CHF as an exemplar has provided useful insights into the 
dimensions and complexities of measuring outcomes in chronic and complex 
conditions. As the burden of chronic disease continues to increase refining the 
metrics of outcome measurements will be equally as important as refining novel 
therapies.  This will be critical to develop and implement interventions to meet the 
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Globally people are living longer with multiple chronic illnesses. This is occurring as 
a consequence of increased longevity and improved medical care options. This 
epidemiological transition from infectious to chronic diseases is placing an 
overwhelming demand on contemporary society [1]. These changes in 
epidemiology and management of disease not only challenge treatment allocation 
but also measures of efficacy and effectiveness of health interventions [2].  
Currently, existing metrics of evaluation at the level of the patient, health care 
provider and health care system are inadequate to meet this challenge [3].  
In managing chronic conditions, there is a need to capture the unique perspective 
of the patient in clinical and therapeutic interactions and to derive outcomes that 
are meaningful to patients, clinicians and policy makers [4]. This is critical not only 
in the assessment and planning of clinical care but also in obtaining useful and 
relevant outcome measures that reflect the patient’s view [4] to promote patient 
centred care.  Patient centred care is defined as “care that is respectful of and 
responsive to individual patient preferences, needs, and values and ensures that 
patient values guide all clinical decisions” [5, p3]. The focus is the patient rather 
than the disease or condition and the priority is no longer the treatment but the 
patient and the individual’s particular health needs [6].  
This thesis investigated outcomes in chronic conditions, using chronic heart failure 
(CHF) as an exemplar; and tested a comprehensive evaluation model from the 
perspective of an organisation, providers and consumers, incorporating patient 
reported outcomes (PROs) that are meaningful and relevant to patients, their 
families, clinicians and policy makers. 
As an introduction, this chapter provides the background to the study, problem 
statement, and study aims. Specifically this chapter discusses the burden of CHF 
and outcome measures important to patients in CHF. It proceeds to explore the 
need for outcomes from patients, providers and system perspectives and discusses 
the need for a more comprehensive approach to outcome assessment that focuses 
on the patients’ perspective. The chapter concludes with an overview of the thesis. 
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1.2 Problem statement and rationale 
Measuring outcomes as an indicator of patient care has been an important driver of 
contemporary healthcare systems [7]. The ageing population and an 
epidemiological shift from acute to chronic conditions have posed an overwhelming 
demand for healthcare infrastructure [1].  This transition has also redefined the 
needs and expectations of healthcare with much of the responsibilities for the care 
falling on the patients and their families [8]. When chronic conditions reach the 
advanced stages, the primary treatment goal is no longer quantity but quality of life 
[9]. Consequently to measure the effectiveness of healthcare comprehensively, the 
traditional outcome measures of health such as mortality and morbidity are seen to 
be increasingly inadequate[10].  
Incorporating the perspectives and preferences of patients about their treatment is 
becoming prominent in setting goals of medical care [9]. Moreover, as complexity, 
burden, and cost of treatment escalate, it is vital that patients and their families, 
clinicians, policy makers and funding bodies have realistic expectations of physical 
as well as psychological and social outcomes [11].   Such expectations are 
contingent on strategies to measure these constructs by means that are reliable, 
valid, relevant, acceptable and have utility amongst patients, clinicians, researchers 
and administrators. 
1.3 Chronic heart failure 
CHF is a disabling and progressive condition and is the final pathway of most heart 
diseases.  The National Heart Foundation/Cardiac Society of Australia and New 
Zealand defines CHF as a: 
“ ..complex clinical syndrome with typical symptoms (e.g. dyspnoea, fatigue) that 
can occur at rest or on effort, and is characterised by objective evidence of an 
underlying structural abnormality or cardiac dysfunction that impairs the ability of 
the ventricle to fill with or eject blood (particularly during physical activity). A 
diagnosis of CHF may be further strengthened by improvement in symptoms in 
response to treatment.” [12] 
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The unpredictability and severity of physical symptoms such as dyspnoea, fatigue 
and oedema has led to adverse health outcomes and distress for patients living 
with CHF [13]. Numerous studies have also shown that CHF is associated with 
depression, and that this association is linked with a worse prognosis [14]. In 
studies with comparative normative data the degree of physical, mental and social 
functioning impairment was greater in CHF patients than other chronic diseases 
sufferers [15, 16].  In fact, many patients with advanced CHF ascribe greater 
importance to quality than to duration of life which may be limited by CHF [9]. 
Furthermore, CHF is the leading cause of hospitalisation in industrialised countries 
[17] with high re-admission rates [18] and prolonged length of stay which all lead to 
an increasing burden on resources both personally for patients, and financially for 
health care services [19].  In developed countries CHF accounts for 1% to 2% of all 
healthcare expenditure [20].  
1.3.1 Burden of chronic heart failure 
CHF is primarily a condition of ageing. As treatment of hypertension, acute 
myocardial infarction and valvular disorders have met with increasing success, the 
incidence and prevalence of CHF has increased dramatically. The prevalence of CHF 
has been shown to increase from less than 1% in the 20-39 years to over 20% in 80 
years and older [21]. In addition the incidence of CHF doubles between 65-74 years 
and 75-84 age bands [22]. Increasingly, ethical and treatment conundrums arise out 
of the need to accurately assess the wishes of patients and their families and 
further tailor services to meet the needs of the vulnerable elderly. [23, 24]  
Despite the progress in the treatment of CHF, the prognosis for people with CHF 
remains poor, with a five-year mortality rate in excess of 50% and ongoing 
symptomatic limitation [25]. Based on a 44-year follow up of the Framingham study 
and 20 year follow up of the offspring cohort, 80% of men and 70% of women 
under the age of 65 years living with CHF die within eight years [21], 30-day 
mortality was around 10%, the one-year mortality rate after CHF diagnosis was 20-
30%, and five year mortality was 45-60%[21]. The lifetime risk of developing heart 
failure is one in five [26]. 
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Patients living with CHF experience a range of symptoms [27], with the majority of 
CHF patients experiencing multiple symptoms concurrently [28, 29]. The most 
common and debilitating symptoms are breathlessness, fatigue [28-31], and 
oedema [27, 29]. Breathlessness and fatigue may impact on social aspects of 
people’s lives [32], and may also cause psychological distress and depression [31]. 
Other symptoms of CHF include insomnia [33, 34], pain [28, 30, 31], palpitations, 
coughing, dizziness [29], and low exercise tolerance [35]. As the illness trajectory 
for CHF is progressive, irreversible and inevitably fatal [36], treatment goals seek to 
prolong life, minimize symptoms and to avoid unpleasant events such as 
hospitalization [37] in a culturally appropriate and cost-effective manner.  
Every year, in Australia alone, more than 30,000 are estimated to be diagnosed 
with CHF[38] and AU$1000 million of the health-care budget  is expended on this 
condition annually [39]. Furthermore, with an ageing population surviving longer 
with the burden of chronic diseases, the expenditure of funds and health care 
expenditure within the elderly age group rises [38].  
Hospitalisations for individuals with CHF are frequent and costly to individuals with 
CHF [40]. People with CHF live with limited quality of life [41] and physical ability 
[41] and the prognosis for CHF is poor [42]. Given the nature of debilitating 
symptoms, and their potential impact on physical, social and psychological aspects 
of life, assessing outcomes important to patients is essential in providing effective 
care.  
1.3.2 Chronic heart failure and evidence based practice 
A diagnosis of CHF presents challenges in caring for the elderly with a chronic 
condition from the perspective of the individual with the condition, their family and 
carers, as well as health professionals and the systems to support them [43]. 
Namely, it is a recurrent, costly and resource intensive chronic condition with an 
illness trajectory punctuated by episodes of decompensation and poor prognosis 
[42]. In spite of extensive evidence, there is evidence of a treatment gap that 
necessitates researchers, clinicians, administrators and policy makers to collaborate 
on strategies to achieve an evidence-based approach to health care [44]. Equally, 
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we are aware that some treatments may impact adversely on patients’ perception 
of quality of life (QoL) in spite of improving more traditional outcomes such as 
mortality [45] . It is important to remember that the definition of evidence-based 
health care relates not only to the best practice treatments, but also to the 
administration of these in accordance with the patient’s values and preferences and 
clinician expertise [46]. Although substantive literature exists in discrete categories, 
such as QoL and health service evaluation, there is considerably less experience in 
the integration and the synthesis of this information to provide an outcome 
measurement model that takes into consideration clinical, organizational and 
patient factors [47].   
1.3.3 Chronic heart failure as an exemplar 
In this thesis, CHF is used as an exemplar condition in order to develop a suite of 
appropriate, relevant and accessible outcome measures to inform patients, 
providers and health care system.  Beyond a diagnosis of CHF, the issues related to 
CHF are germane to many conditions of both malignant and non-malignant origin 
[48]. Many of the issues faced by people with CHF strongly relate to ageing, frailty 
and comorbid conditions and outcomes are influenced by socio-economic and 
cultural factors [26]. Conditions, such as chronic obstructive pulmonary disease, 
diabetes and many cancers have many similarities with CHF from the perspective 
that they are chronic progressive life limiting illnesses, cause a high symptom 
burden and have a significant impact on caregivers and the health care system [48]. 
There is a clearly defined need for investigating outcome assessment in chronic 
illnesses where often the patients’ perception of QoL are adversely impacted 
despite the improvement in more traditional outcomes such as mortality. 
Moreover, the complexity of clinical care and the assessment of additive 
treatments increase the need for increasingly sophisticated forms of measurement.  
These data need to be relevant and interpretable to patients, providers and health 
care systems. For example, in the United States (US), the Patient-Centered 
Outcomes Research Institute (PCORI) has been established by the US Congress to 
conduct research to provide information about evidence to help patients and their 
health care providers make more informed decisions [49].  This is largely driven by 
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the perception of individuals and the assessment of patient reported outcome 
measures [2] which provide the view of the individual.  
1.4 Outcomes 
Outcomes are defined as the results of care [50]. They are used to gain 
understanding of CHF at every facet of its trajectory and any associated health care 
intervention. Outcomes are utilised at all levels of care by describing, interpreting 
and predicting effects of health care practices and interventions. Outcome 
assessment is directed at meeting three objectives; (1) to assess the efficacy of 
treatment/care of individuals as well as effectiveness; (2)  to help in managing 
health service delivery and monitoring its quality; (3) and to support priority setting 
and policy development [50].  
Traditionally clinical outcomes such as mortality and morbidity have been used in 
clinical trials and also widely reported as progress against the burden of CHF at all 
levels of care. Generally the reason for frequent use of mortality and morbidity may 
have been due to the fact that they reflect the natural history of the disease [51]. 
With the epidemiologic transition from infectious to chronic diseases and increase 
in life expectancy, these outcomes are seen to be increasingly inadequate [2]. 
Although they are intuitively easy to understand, these clinical outcomes have been 
associated with crucial shortcomings such as limited insight to the values of 
patients. Moreover, many individuals are living with more than one chronic illness. 
Consequently there is a growing recognition to supplement outcomes such as 
mortality and clinical events such as morbidity with PROs such as QoL and 
symptoms to facilitate understanding not just of survival but also of suffering 
caused by CHF. 
1.4.1 Patient reported outcomes 
PROs refer to information reported directly from the individual affected by a health 
condition and treatment received. It is an umbrella term to capture outcomes that 
are based on patients’ direct perception, interpretation and evaluation of their 
condition as well as care and services received [52]. Hence PROs encourage 
patients’ participation. PROs extend beyond traditional outcomes to include results 
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that are significant to patients. In fact, PROs such as patients’ perceptions of their 
health have been found to be important indicators of health [53]. Usually, PROs are 
a multidimensional construct assessing various perspectives on disease and 
treatment including patient preferences, QoL, symptoms, functional status, 
psychological well-being, treatment adherence, and satisfaction with treatment by 
means of a self-completed questionnaire.  Although there are clear differences in 
definitions, PRO measures, QoL or HRQoL questionnaires are commonly used 
interchangeably [54].  
The aim of PROs are to assess the patient's perspective of health, illness, and the 
effects of health care interventions in a reliable, valid, acceptable, and feasible way 
[55].There is a growing belief that PROs have the potential to improve CHF care by 
promoting patient centred care [55]. By assessing PROs in a rigorous and valid 
manner, individual patient care will improve as better information about the effect 
of care is available [55]. Subsequently this will improve the decision making process 
[55]. Furthermore PROs have the potential to influence health policy and the 
allocation of healthcare resources [56]. However, in spite of the endorsement in 
policy, data suggests that they are not widely influencing practices [57]. In using 
PROs, many challenges exist such as concerns over the quality of the measures, and 
the wide variations in standards of study design and reporting that may lead to 
difficulties in interpreting PRO data [55].  
1.4.2 Patient important outcomes 
Patient important outcomes (PIO) can be defined as outcomes that patients notice, 
cares about and for which they would be willing to undergo a treatment with 
associated risk, cost, or inconvenience for it to be the only thing that change [58]. 
The drive to improve the quality of care has led to the realisation of the importance 
of patient’s perspective and hence the use of PROs. However PROs are not the 
same as PIO. Despite the importance of PROs as an outcome measure in CHF, PROs 
currently available have been developed and driven predominantly by clinicians or 
researchers [59]. It is also important to remember that PROs may not be the only 
outcomes that they value. Patients, at the centre of care, should be able to identify 
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an outcome important to them that might not have been considered by 
practitioners or even researchers.   
With a growing interest in patient centred care, seeking to measure outcomes that 
are important to patients is a natural consequence [49]. It has been suggested that 
clinical outcomes such as mortality and morbidity in addition PROs such as 
satisfaction with care and functioning and health status need to be tracked for 
patient centred care [7].   
1.4.3 Outcomes from different perspectives 
In assessing and monitoring health care effectiveness and efficacy, a range of 
outcomes important to key stakeholders of health care (patients, provider and the 
health care system) need to be considered especially if they are to influence policy, 
practice and future research. The perceived importance of different CHF outcomes 
will vary from the vantage point of patients, providers and system. From the 
perspective of patients, the QoL may be the most important outcome, whereas 
clinical outcomes may be the most frequently used amongst health care providers. 
For health care systems, outcome of the greatest consequence may be the 
economic cost. One of the main areas of interest would be whether the outcomes 
deemed to be important to patients are also important and meaningful to providers 
and health care system and the possible methods of integrating these outcomes.  
It has been recognised no single outcome can capture all elements of a complex 
syndrome such as CHF [60] nor provide all required information for all stakeholders 
of CHF care. Assessing outcome measures that include PROs to develop a core set 
of outcome measures that are relevant and meaningful to all key stakeholders 
would potentially influence policy, practice and research. In addition, integrating 
these data into a single composite outcome may be a step forward in providing 
robust but simple information that reflect the benefits and burden from the 
viewpoint of each stakeholder group. 
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1.4.4 Composite outcome 
A composite outcome is where multiple outcomes are combined into a single 
outcome measure [61]. Implicit in the definition is an expectation that each of the 
component outcomes would measure the same underlying pathophysiology, but be 
different enough that they add a dimension to the measurement of the disease 
process that has not been contributed by any other component outcome [62]. The 
composite outcome derived would consist of a set of outcome measures 
meaningful to all participants of the health care.   
1.5 Study aims 
Using CHF as an exemplar, this thesis reviews, integrates and synthesizes outcome 
measures to propose a core set of outcomes that takes into consideration patient, 
clinical and organizational perspectives. This thesis also extends the concept of 
PROs to considering the option of those that are important and meaningful to the 
patients (PIOs). Furthermore, current models that have tried to incorporate 
outcomes that may be more meaningful to a wider variety of stakeholders will be 
tested using data from a contemporary CHF clinical trial. This objective was 
achieved by conducting a series of sequential studies. Specifically this study sought 
to:  
 Examine patient reported outcomes in clinical management and in clinical 
research (Chapters 2 and 3). 
 Investigate patient important outcomes, their utility, relevance and 
acceptability  amongst patients, clinicians, researchers and administrators 
(Chapter 4) 
 Test composite outcomes model that integrate patient important outcomes 
using the data from clinical trials research (Chapter 5). 
1.6 Overview of the thesis structure 
To achieve the aims above, Chapter Two is an integrative review of PROs as an 
outcome measure to influence policy decision. The PROs measure, for example, 
health related quality of life (HRQoL), symptom, functionality and spirituality will be 
explored for conveying important and unique information for CHF policy decision. 
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Despite recognition of PROs and exponential usage in clinical trials, its use is limited 
in clinical practice and minimal in policy domain. This chapter describes how PRO 
measures compliment the traditional clinical outcome measures in conveying 
important information for policy makers to enact the vision of a patient centred 
care. 
Despite multiple utility of PROs measure in CHF, the primary area of application has 
been in clinical trials, particularly of HRQoL. Chapter Three will be assessing the 
methodological and reporting quality of HRQoL assessment in CHF clinical trials. 
This chapter addresses methodological and reporting rigour of HRQoL assessment. 
Chapter Four provides a review of the PIOs in CHF across the illness trajectory. This 
is to examine the meaningful outcome measures applied in CHF and identify the 
strengths and weaknesses of approaches to each outcome measure. Furthermore, 
this chapter recommends the core set of outcomes consisting of PIOs that are also 
meaningful to providers and health care system. 
Chapter Five reports on methodological and weighting issues in composite 
outcomes combining set of PIO measures identified in Chapter Four using data from 
the Which Heart failure intervention is most Cost-effective & consumer friendly in 
reducing Hospital care (WHICH(?)), a multicenter, randomised controlled study 
[63].This chapter proceeds to describe derivation and its implication on interpreting 
these composite outcomes.  
Chapter Six provides a discussion of the study findings and provides conclusions 
based on the investigations undertaken as part of the doctoral thesis. It will 
particularly focus on summarising and discussing the outcome assessments and its 
implication to policy, practice and research. 
1.6.1 A note on the format of the thesis 
References are presented at the end of each chapter and publications related to 
chapters are presented in the appendices with the permission of the publishers and 
ethical approvals. In order to facilitate reading and interpretation, some issues are 




This chapter has described the inadequacy of traditional outcome measures to 
evaluate health outcomes in common, chronic illnesses with a high comorbidity 
burden. In addition, this chapter has depicted the burden of CHF and the need to 
capture the unique perspective of the patient in clinical and therapeutic 
interactions and also derive outcomes that are meaningful to patients, clinicians 
and policy makers especially in the management of chronic conditions. The 
following chapter will use the method of an integrative review to identify and 
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Chapter 2 The role of patient reported outcomes in 





Chapter 1 provided an introduction to the thesis and emphasised the importance of 
PROs in driving efficient, effective and equitable services [1]. Traditionally, a range 
of outcome measures have been used to communicate health care quality including 
treatment effectiveness and patient centeredness using incidence, mortality and 
morbidity [2]. However, these measures fail to express the burden experienced by 
CHF patients. One of the reasons may be that they focus exclusively on the 
clinician’s perspective of CHF treatment as these measures are derived from data 
sources documented by the clinicians and other health professionals. Accordingly, 
there is clearer information on CHF mortality or hospitalisation than on issues such 
as HRQoL or satisfaction with care as experienced and reported by patients [3].   
To date, the focus on PROs has been from clinical trials and individual studies, yet 
there is limited inclusion of the patient perspective in routine clinical decision 
making. Outcome measures at the patient level facilitate policy makers to balance 
the societal benefits and costs [4].  Moreover, a number of qualitative studies and 
reviews have underscored the need to focus on individual’s needs. The subjectivity 
of this assessment and the inability of health professionals to evaluate this for their 
patients have been demonstrated in many settings. The US multicentre SUPPORT 
(Study To Understand Prognoses and Preferences for Outcomes and Risks of 
Treatment) study [5] has provided evidence of the disparity between physicians’ 
description of severity of symptoms and that of patients.  
Consequently there is a need to track and analyse a range of outcome measures 
important for not only individual clinical decisions but for policy decision as well. In 
addition, an informed decision making at macro level will reduce unnecessary 
expenditure by minimising overuse/misuse of health care services or more critically, 
underuse that result in dire consequences for the individual.  Although there is a 
gradual recognition of the relevance of PROs in decision making in the health care 
system, PROs are not routinely collected and analysed and hence PROs have had 
limited influence on policy decisions [4]. 
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2.2 Global burden of chronic illness (Non-communicable diseases) 
At a global level the burden of non-communicable diseases (NCDs) are increasingly 
recognised. NCDs are responsible for 63 percent of all deaths around the world [6].  
Not only do NCDs exert an enormous health problem, but they also have serious 
socioeconomic consequences [7]. Therefore mechanisms of monitoring  
surveillance and outcome assessment are needed [8].  Increasingly governments 
and policy makers are presented with treatment allocation challenges. 
Technological innovation is occurring at an unprecedented rate in cardiovascular 
care challenging resource allocation and workforce availability. Increasing fiscal 
constraints and paradoxically the need to provide innovative, acceptable, state–of-
the-art care is complex [8].  Balancing these needs in the context of a consumer and 
market driven society is a delicate balance for health care policy makers and health 
professionals, particularly within a context of the need to decrease health 
disparities and promote equity of access. 
This chapter presents an integrative review to summarize how PROs have been 
defined, measured, and used in CHF research and discusses their implication in 
policy decisions.  Moreover, it provides a discussion of the Innovative Care for 
Chronic Condition framework as a mechanism for improving outcomes at a macro, 
meso and micro level for chronic conditions [9].  
2.3 Rationale for the increased focus beyond morbidity and mortality 
Ageing and the increasing burden of NCDs, including heart disease, respiratory 
conditions and stroke are influencing strategic policy initiatives in both developed 
and developing countries [10].  These factors also challenge clinicians and policy 
makers to consider health and social outcomes beyond traditional concepts of 
morbidity and mortality. Rapidly growing disciplines, such as health economics, 
strive to balance parameters of demands, costs, and benefits relative to patient 
outcomes and treatment allocation [1, 11]. Yet there is discussion and debate of 
these approaches and the need to capture the needs at the level of the individual. 
Clinicians and policy makers are increasingly aware of the complex interplay of 
social, economic, physiological and policy factors in determining health outcomes 
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[12-14].  The dilemmas confronting contemporary society underscore the need to 
increase the links between researchers and policy makers to develop, evaluate and 
implement appropriate interventions. [15] As well as assessing clinical outcomes, 
we also need to capture the unique perspective of the individual and their social 
determinants of health, to effectively inform health care planning. [16] This is of 
particular significance in chronic and aged care conditions where psychological and 
social issues play an important role in aetiology and prognosis [17, 18].    
Balancing treatment burden in the elderly is of concern and often gains in longevity 
are not matched by symptom relief and QoL.  [19] The health status of a population 
has traditionally been measured in terms of mortality and morbidity rates. Yet, with 
the epidemiologic transition from infectious to chronic diseases, quantifying health 
in terms of death and disease rates is seen to be increasingly inadequate.  [20]  
Moreover, the ageing of the population means that a greater proportion of the 
population will receive treatment for chronic disease for a longer period of time. In 
chronic diseases, the goal of treatment commonly changes from cure to control of 
symptoms through targeted interventions [21].  
2.4 Patient reported outcomes 
As discussed in Chapter One, the increasing complexity of treatment allocation, 
acceptability and utility makes the views of consumers more critical in intervention 
development, evaluation and health service planning. [22] One way to achieve this 
perspective is through assessing PROs. This term refers to information and 
measures reported directly by the individuals affected by a health condition, 
treatment or life experience [23]. PRO captures the patient’s perceptions of the 
broad spectrum of diseases and treatment outcomes.  HRQoL is one of several 
types of PROs. Others may include symptoms, treatment adverse effect, functional 
status, and overall well-being. For example, capturing information to bathe without 
assistance and participate in activities of daily living is important in determining the 
impact of an intervention.  Further, if an individual is unable to either fill their 
medication prescription or open the medication container pharmacotherapy is 
unlikely to be effective.   
 
23 
Despite benefits of a proposed treatment there is also the risk of an intervention 
having deleterious effects on the individual’s QoL and capacity to undertake 
activities of daily living. In such a case, the cure can be worse than the disease.  
Likewise, extended life can mean living for a prolonged period with a disability [24]. 
As complexity, burden and cost of treatment escalates, it is vital that patients and 
their families, clinicians, policy makers and funding bodies have a realistic 
expectation of outcomes, not merely in relation to the physical, but from a 
psychological and social dimension as well [25].   Gathering the unique perspective 
of patients and their families is paramount.  These data will be crucial in informing 
policy makers to plan and implement strategic initiatives. Therefore it is increasingly 
an important consideration that the unique perspective of the patient be 
represented not only individual clinical encounters, including patient assessment, 
but also in health policy, clinical trials and health service evaluation  [26].  
Patient reported outcomes can be either generic or specific to a clinical condition or 
disease state. Often the term “PROs” has been used to refer to the concept being 
measured, the instrument used to measure the concepts and the actual endpoint. 
There is a need to distinguish the concept and outcome one is attempting to 
measure and the endpoint for statistical analysis [27]. It is important to remember 
the PROs concept is the very specific goal of the measurement. It is vital to have 
sufficient evidence that PRO concept is adequately measured by a PRO instrument 
[28]. In recent decades there has been an exponential growth in the measures and 
it is important to consider not only the psychometric properties but also the utility 
in making treatment decisions and policy development. 
2.5 Innovative Care for Chronic Conditions framework  
The Innovative Care for Chronic Conditions (ICCC) framework (Figure 2.1) has been 
empirically derived to help reorient health care systems to manage the demands of 
the rising burden of chronic conditions around the world [9]. This model has been 
associated with improved health outcomes at the level of the patient and health 
care system [29]. At the centre of the framework is the healthcare triad (micro level 
of care); the partnership between patients and families, health care teams, and 
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community supporters.  This recognises the importance of patient centred care and 
recognises the need for partnerships in improving health outcomes [29]. 
 
Innovative Care for Chronic Conditions Framework
Building Blocks for Action Innovative Care for Chronic Conditions: Global Report. World Health Organisation 2002.
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Figure 2.1 The Innovative Care for Chronic Conditions (ICCC) framework 
The Chronic Care Model involves six pillars: community focus where health care 
services interface with the community; health systems that support management of 
chronic conditions; self-management support incorporating a comprehensive 
behavioural strategy which empowers and prepares people to manage their health 
and health care; delivery system redesign, where roles and expectations are 
clarified; decision support with ongoing development of strategies to manage 
decision making; and clinical information systems, allowing the tracking of patients.  
Integral to each of these dimensions is the assessment and evaluation of the 
perspectives of patients.   
To achieve optimal outcomes this triad needs to be supported by the broader 
community and the integrated health care organisations (meso level of care). This 
in turn needs to influence the broader positive policy framework (macro level of 
care) and to be influenced by them. It is contingent on every member of triad 
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(patients and families, health care teams, and community supporters) being 
informed, and to maintain communication and collaboration.   
The ICCC framework emphasizes the importance of patients and families, forming 
one-third of the key ‘partnership triad’ at the most basic level. Furthermore, 
because management of chronic conditions requires lifestyle and daily behaviour 
changes, emphasis needs to be placed on the patient’s central role and 
responsibility in health care. When we refer to the patient, we consider family 
members and carers as part of this unit. Inclusion of this important dimension is 
contingent upon developing and testing of a model that measure the patient’s 
unique perspective. 
2.6 Value of patient reported outcomes in policy decision 
As discussed above, PROs in the context of health care have become an increasingly 
important focus of regulatory bodies and health care administrators [25]. The 
potential for interventions and treatments to be assessed from the perspective of 
the patient through validated psychometric measures is a critical issue for clinical 
practice, outcome evaluation and research. At a conference to assess the 
contribution of the Agency for Health Care Policy and Research (AHCPR) in 
enhancing outcomes, it was concluded that researchers and policy makers need to 
build upon descriptive studies and methodological advancements with the goal of 
measurably improving outcomes, quality, and efficiency of care [30]. Developing 
this science is dependent upon collaboration between consumers, academics and 
clinicians from a range of disciplines, particularly health sciences and biostatistics, 
as well as policy makers and administrators.  
2.7 Purpose of the review 
To provide more in depth discussion of PROs and how these can inform the metric 
that assists policy makers in developing and implementing health policy within the 
context of CHF, an integrative review was undertaken.  As mentioned in previous 
chapter, living with CHF commonly includes high levels of ill-health, disability and 
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mortality placing a heavy burden on health services. A number of qualitative studies 
and reviews have demonstrated that that living with CHF was characterized by 
distressing physical and emotional symptoms, compromised physical functioning, 
altered social and role dysfunction and living with uncertainty [31-35] . Given the 
nature of debilitating symptoms, and their potential impact on physical, social and 
psychological aspects of life, assessing PROs in CHF seems appropriate. 
This review summarizes how PROs have been defined, measured, and used in CHF 
research and identify their possible implications for policy initiative. The electronic 
databases CINAHL, Medline, EMBASE and the Internet were searched using key 
words including ‘heart failure’, ‘instruments’, ‘psychometric instruments’ and  
‘patient reported outcomes.’  Furthermore the reference lists of published 
materials were hand searched for additional data sources. The aim of the review 
was to explore patient reported outcomes measures in CHF that may provide new 
insight in policy decisions. A range of measures contributing to the impact of the 
outcomes of CHF, such as medication adherence and self-management were 
explored.  Inclusion criteria were those papers that explored PROs measures that 
would provide new dimension in outcomes of CHF. Exclusion criteria were papers 
not published in English.  Abstracts were appraised that most fitted the aims of the 
review and met the inclusion criteria.  
2.8 Utility of patient reported outcomes  
Examples of commonly used PROs were provided to illustrate the importance of 
including these issues in policy decisions. Table 2.1 provides examples of the 
constructs that assess the impact of CHF on an individual, ranging from limiting 
activities of daily living through to existential distress.  Although this list is not 
exhaustive it provides insight into the range of measures available.  Despite many 
potential uses of PRO measures in CHF, the primary area of application has been in 
randomised clinical trial investigation, particularly HRQoL. This is in line with the 
recognition that the changes in physiological measures may not always translate 
into a tangible benefits perceived by the patients. On closer inspection of these 
measures, outcomes important to patients are affected not only by symptoms and 
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disease severity but also by a complex interaction of physical, social and 
psychological factors. By incorporating patients’ perspective they account for 
differences, subjective as well as objective among individual patients and to cater 
for patient’s preference. When the individual is unable to complete such measures, 
the use of proxies can be considered. 
Table 2.1 Examples of PROs in CHF 
Construct Definition Disease specific 
examples 
The impact of CHF on an 
individual 
Health related 
quality of life 
(HRQoL)  
HRQoL concerns 
attributes of life 
valued by patients, 
such as level of 
















with Heart Failure 
Questionnaire [37] 
the Chronic Heart 
Failure Questionnaire 
(CHQ) [38] and the 
quality of life 
questionnaire in 




Patients with CHF often 
experience a burden of 
disease that has a 
negative effect upon 
their health-related 
quality of life. The 
important goal of 
increasing the length of 
healthy life 
demonstrates a change 
from just measuring 
mortality and morbidity 
to also include health 






or status usually 
refers to ability to 
participate in 
everyday activities, 
in distinction to 
psychological 
aspects of quality 
of life such as 
perception of 
health. [42]  
Self-reported 
functional status in 
CHF patients is 
usually assessed by 
using subscales of 
quality of life 
questionnaires.  [39] 
How much symptoms 
(and psychologic 
distress) commonly 
associated with CHF 
limit physical, social, 
role, and mental 
function. It also 
incorporates the effects 
of extraneous factors 
such as personal 
motivation which may 
not be able to be 





refers to feelings of 
dysphoria, 
A variety of self-
report and interview 
measures have been 
used to assess levels 
It is only recently that 
attention to the 
psychosocial issues of 
CHF including stress, 
 
28 
Construct Definition Disease specific 
examples 
The impact of CHF on an 
individual 
anxiousness, worry, 
and other negative 
psychologic 
reactions 
to illness ([43]) 
of depression in CHF 
including a range of 
generic instruments. 
The CDS is a self- 
report, 26-item self-
rating scale, which 
measures depression 
specifically in cardiac 
patients and may be 
used to measure 
depression in 
patients with CHF.  
[44] However, it 
should be noted that 
somatic depression 
symptoms of fatigue 
and insomnia 
included in the CDS 
are also primary 
symptoms of CHF. 
anxiety and depression 
had increased. These 
factors have been 
related to coping styles 
and physical health of 
patients with CHF. 
Besides predicting 
cardiac events and 
affecting mortality, it is 
possible that depression 
may contribute to the 
high readmission rates 
for patients with CHF.  
[45, 46] 
Spiritual/existential Reference to 
spiritual and 
existential issues 
refers to the search 
for meaning, 
purpose and 
fulfilment in life. 
[47, 48] 
Spirituality in HF 
patients is assessed 
by Spirituality 
Assessment Scale 
(SAS), which is a 
generic instrument or 
using a qualitative 
method which allows 
a deep 
understanding of the 
social and illness 
experience of HF 
patients.  [49] 
Spiritual beliefs serve as 
a buffer for stressful 
physical and emotional 
events associated with 
chronic illness in HF 
patients [50]. Spirituality 
has also been linked 
with the adjustment of 
patients with severe 
CHF. [48] 






illness and disease. 
[51]) Patients with 
a chronic illness 





developed by Riegel 
et al for evaluating 
the self-management 
abilities of HF 
patients. [52] 
Self-care can have 
positive lifestyle 
modification effect, on 
response to worsening 
symptoms and on 
coping with chronic 
illness.  [53]. All of these 
will lead to fewer 
problems leading to 
readmission or 
unnecessary visits to 
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Construct Definition Disease specific 
examples 
The impact of CHF on an 
individual 
primarily to 
manage what may 
be a precarious 
balance between 




Self-efficacy Self-efficacy is the 
judgment that 
individuals develop 
about their own 
ability to 
successfully 
perform a given 
behaviour.   
The Heart Failure 
Self-Efficacy 
Scale–30 (HFSE-34) is 
a disease specific 
instrument and 
contains 5 subscales 




and activity and HF 
readmissions.   [54] 
Self-efficacy has been 
demonstrated to be a 
marker of cardiac 
function and has been 
demonstrated to predict 
mortality and 
hospitalisation [55]. Self-
efficacy is increasingly 
used as a predictor of 
behaviour and 
adherence.  [56] 
Satisfaction Satisfaction can be 
defined as the 
extent to which 
individuals perceive 
either positively or 
negatively the 
impact or delivery 
of a health 
intervention.  [57, 
58] 
 






satisfaction with CHF. 
Patient satisfaction 
has been measured 
only as a part of a 
battery of “outcome” 
measures, such as 





interventions such as 
video-consultations.  
[59, 60] 
Patient satisfactions can 
be used as an endpoint 
that explores affability, 
accessibility and 
availability of high 




defined as the 
extent to which a 
person’s behavior 
The HF Compliance 
Questionnaire 
(HFCQ) and its 
revised version (The 
Poor treatment 
compliance among HF 
patients has been linked 
to increased mortality 
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Construct Definition Disease specific 
examples 
The impact of CHF on an 
individual 
coincides with 









the quality of the 
patient-provider 
interaction. [62, 63]   
HFCQR) have been 
used to measure 
patients’ adherence 
to medical regimen.  
[64] 
and morbidity rates and 
increased health care 
costs associated with 
increased outpatients 
care as well as hospital 
readmission. [63] 





and memory.  
There is strong 











functioning are used 
in CHF.[66] 
It is estimated 25% to 
50% of HF patients have 
cognitive impairment 
[65]. HF has been 
proposed a s a possible 
cause of cognitive 
function, expressed as a 
term ‘cardiogenic 
dementia’ [67] 
Social support Social support 
refers to the 







Social support has 
been assessed in CHF 
and identified as a 
predictor of 
outcome. [69] 
Social support influences 
symptoms and 
functional status, health 
[perceptions [70]. It 
would facilitate 
management of 
symptoms such as 
fatigue and cognitive 
impairment. [36] 
Carer  outcomes Carers play a 
critical role in 
supporting 
individuals with 
CHF and this can 
have both positive 
and negative 
health, social and 
 A number of 
caregiver 
instruments are 
available to assess 
caregiver outcomes. 
[72]  
Caregivers play an 
important role in the 
care of patients with HF, 
hence caregiver 
contributes to patient 
outcomes [73]. Lack of 
caregiver support has 
been shown to be 
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Construct Definition Disease specific 
examples 




associated with higher 
rates of hospitalisations 
for patients with CHF 
[73]  
Social capital Social capital 
relates to networks 
and relationships in 








The issue of how 
social capital is lined 
to health and disease 
including CHF 
remains uncertain 
although the strong 
association between 
social determinants 
of health and 
outcomes make this 
of an increasing 
interest and 
concern.[75] 
Social capital is 
associated with quality 
of life especially in an 
old age [76]. Also social 
capital has been shown 
to be linked to health 
care utilisation and 
demand [77] 
Resilience Resiliency refers to 
a person 
successfully 
adapting to adverse 
life events or 
circumstances or 
both.  [78] 
Resilience of the 
patient to CHF is 
poorly studied, 
although hope has 





vulnerability in CHF 
patients [80] 
Needs  Needs assessment 










(NHNA) has been 
designed to 
specifically assess the 
health needs of 
cardiac patients. [82] 
The Heart Failure 
Needs Assessment 
Questionnaire has 
also been developed 
specifically for 
individuals with CHF. 
[81] 
Provides information on 
patients’ perceptions of 
their existing health 
status and unmet needs 
in current management 
plan [81]. Guides 
planning and projection 
of  needs of patients and 
population [81] 
Importantly, PROs extend beyond traditional clinical efficacy and adverse effects 
and represent the patient’s perspective on the impact of disease and its treatment 
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on daily functioning and wellbeing. [83]  In many situations patient report is the 
sole source of data on frequency and severity of symptoms and also the side effects 
and the impact of treatment on functioning and well-being [84]. Hence they are 
managed and monitored almost entirely on patient reports. Indeed in conditions 
where there are no physical or physiological markers of disease activity, PROs 
become the outcome of choice for evaluating disease activity and in providing 
comprehensive understanding of severity of symptoms and their impact on daily 
functioning and well-being.   Palliative and supportive care is a striking example of 
such a strategy [80, 85-87]. 
However, it is not uncommon for there to be a mismatch between the patient’s 
perception and the clinician’s assessment [81].  For example, in some instances the 
patient’s perception of CHF and disease severity has also been overestimated when 
compared to the physician’s clinical findings [88]. This incongruence may be due to 
the validity of tools used to assess patient perception or, an underestimation by 
clinicians of patient’s with CHF.   
Therefore valid and reliable PROs can be an important communication tool. These 
measures provide a useful way to gather and communicate evidence about 
treatment risks and benefits.  This information can be used to highlight particular 
treatment benefits or to provide a way to differentiate the patient benefits among 
competing treatments with similar clinical efficacy [89].  This will assist clinicians in 
providing patients with better information about potential effects of treatment, 
and thus lead to better treatment decisions. Data derived from PROs can also 
enable patients to increase their understanding about their illness and treatment 
risks and benefits. This is also a potentially useful strategy in increasing individuals’ 
participation in their own treatment and in health care decision making. Patient 
adherence is a major impediment to the effectiveness of therapies. Increased 
patient satisfaction with a treatment has been shown to be related to adherence 
[17]. Accordingly, evaluating satisfaction with treatment may assist health care 
providers in understanding the issues influencing treatment adherence and may 
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help identify aspects of the management plan that require improvement to 
enhance long term treatment outcome [90].  
The ICCC framework (Figure 2.1) describes the importance of community and policy 
aspects of improving health care for chronic conditions [91]. This model highlights  
the importance of considering discrete yet linked attributes at the micro (patient 
and family), meso (health care organisation and community), and macro (policy) 
levels, underscoring the need for a multifaceted approach to health care outcome 
assessment. To date, a comprehensive model for health service evaluation 
including all these critical elements has not been tested. 
Patient assessments are important elements of the evaluation of treatment impact, 
alongside other clinical indicators. Bioethics has emphasised the importance of the 
patient’s point of view in health care decisions through its call to respect patient 
autonomy.  Outcome research has specified the importance of the patient’s 
perspective on the goal of medical care in its bid to accentuate patient-centred 
outcome such as QoL [81]. It is recognised that linking patient-reported health with 
physiological markers of disease provide not just unique information in patient 
care, but also help to determine the severity of disease and monitor the trajectory 
of illness [92]. These factors are also important in informing cogent policy decisions.   
It is hard to dispute that the science of PROs is advanced, as illustrated in the vast 
numbers of psychometric instruments available to assess these items. Perhaps 
what remains is the greatest challenge; moving assessment of these constructs 
beyond the research setting to routine clinical practice and perhaps as a part of 
administrative data collection that will inform clinical and policy makers.  
The relevance of the applicability of clinical trial evidence to real world populations 
is commonly questioned [93]. Often participants in clinical trials are commonly 
younger, have less comorbid conditions and commonly do not have the challenges 
of poor health literacy and cognitive impairment that impact on outcomes of CHF 
[94]. This conundrum is illustrated in the adverse events related to 
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pharmacotherapy when agents move from the clinical trial to the usual care setting 
[95]. 
Registry data provides a useful insight into real world situations that can provide 
policy makers with reliable and valid data to inform policy decisions.  A number of 
registries have provided useful data to inform CHF management in the real world 
setting [96-100]. Many of these registries provide useful data – particularly relating 
to how factors such as socioeconomic determinants, level of insurance, and 
ethnicity impact on health related outcomes. [101] Data for these registries is often 
collected from administrative data sets that do not routinely use PROs. Including 
valid and reliable PROs in these data sets may be useful in health service planning. 
2.9 Innovative Care for Chronic Condition framework and policy decision 
As shown in the ICCC Framework in Figure 2.1, a Positive Policy Framework is 
contingent upon understanding the needs of patients and their families. This can be 
achieved through a range of means, such as community consultations, 
representations of democratically-elected candidates and lobbying from particular 
consumer organisations. A potentially more equitable, just, reliable and valid 
mechanism would be to include PROs in routine clinical assessments, clinical trials 
and registries to allow an informed decision on how conditions, treatment and 
health care interventions impact on the lives of individuals and their families. For 
example, in Australia, the most rapidly increasing population are centenarians - 
many of whom will endure and die of CHF. Yet, we know little of their needs and 
service planning requirements. [102]  Further, the development of reliable and valid 
metrics that allow for the integration of micro, meso and macro elements of health 
service delivery are needed. Health care policy, often constrained by partisan 
politics and influence of powerful lobby groups, can struggle to keep pace with the 
strategies needed to administer and monitor the increasing expense and 
complexity of healthcare [103].  In CHF, the development of innovative treatments, 
such as implantable cardiac defibrillators, left-ventricular assist devices have 
outpaced the debate and discussion of the applicability and relevance to particular 
groups [80, 104]. Despite benefits some patients may derive from these medical 
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interventions, the default plan of providing these devices or procedures regardless 
of patient’s wishes and priorities need to be re-examined by policy makers. 
Furthermore, their use entails substantial financial, physiological, and psychological 
costs to patients, health care system and community in general.  
Policymakers and clinicians alike need to allocate limited resources to patients with 
CHF to serve their interests and perspectives. Understanding the impact of these 
interventions on individuals is likely to be critical in the future and require extensive 
debate and discussion.  Evidence based policy making is dependent on the 
weighting of a range of issues including cost, measures of effectiveness, equity and 
also the perspectives of patients and caregivers.  Moreover, it is important to 
consider the use of PROs in individuals who are cognitively impaired or from 
culturally and linguistically diverse groups [36, 105, 106].  
2.10 Chapter summary 
This chapter has summarised PRO measures and their utility in CHF research and 
considered the implications for policy initiative.  It has demonstrated that there a 
numerous PROs assessing a diverse range of constructs. Effective policy and 
planning of health care services is dependent on being informed of the impact on 
the individual and their families.  This should be derived from prospective, rigorous 
measures not ad hoc views and more importantly the sole perspective of health 
professionals. 
The ICCC has been introduced as an important framework to improve the 
management of chronic illnesses.  This model is designed to compel policy makers 
to make decisions about service supply and health care spending that reflects the 
balance of extending life with improved quality, a critical issue considering the 
increasing global burden of chronic illnesses.  As HRQoL is considered to provide a 
multifaceted perspective of the individual living with a condition, the following 
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Chapter 3 Methodological and reporting rigour of 





The previous chapter has identified and discussed wide range of PROs that would 
be useful in incorporating a person centred approach to care. As the burden of 
chronic conditions increase as the population ages, a need to develop and refine 
the metrics that includes the perspectives of patients at an individual and a 
population level becomes critical. Effective evaluation of the efficacy of health care 
intervention, treatment and planning will lead to health policy decisions on service 
provision and health care spending that will foster extending life with improved 
quality.  
As discussed in Chapter Two, there are numerous PRO measures in CHF with the 
aim of increasing the patient’s voice in their own health care. The use of such 
instruments, especially those measuring HRQoL has increasingly been 
acknowledged as crucial for evaluating the overall treatment effectiveness in 
clinical trials. Information such as physical and psychological problems, adverse 
effects of treatment, and social limitations are invaluable as they provide patient’s 
perspective [1].  
PROs as used in clinical trials have highlighted a wide range of benefits if applied in 
clinical practice, such as increase health practitioner’s awareness of and ability to 
address patients’ concerns and their preferences [2] and improve communication 
[3] and hence support shared decision making [3]. Despite these critical benefits, 
the translation of PROs from clinical trials to their use in clinical management has 
been limited. The reason for this slow uptake may be due to the heterogeneity in 
reporting of key HRQoL methodological factors in clinical trials which may have led 
to inability to appreciate or to interpret these measures competently amongst 
health care providers [4, 5]. Moreover, there is potentially inherent scepticism of 
health professionals and policy makers on the utility of this approach. Investigating 
the intent and psychometric approaches is necessary. 
There are currently several generic and disease-specific HRQoL questionnaires used 
in CHF trials. Examples of generic measures used in CHF trials include The Medical 
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Outcomes Study (MOS) Short Form 36-item Health Survey [6, 7]and Sickness Impact 
Profile[8] and European Quality of Life instrument (EQ 5D) [9]. Measures of heart 
failure specific measures include Minnesota Living with Heart Failure Questionnaire 
(MLWHF) [9] and the Kansas City Cardiomyopathy Questionnaire [10] to name a 
few. They have all demonstrated acceptable levels of reliability, validity, 
responsiveness and acceptability for CHF population [11]. However reporting 
HRQoL in clinical trials requires more than specific information on the psychometric 
robustness of the tool for the specific trial population. Considerations such as on 
data collection, appropriate timing of assessment, adequate statistical analysis and 
outcome interpretation are all crucial to influence decision making.   
3.2 Background 
Chronic heart failure is a common, costly and resource intensive syndrome with a 
poor prognosis. Patients with CHF experience poor outcomes including severely 
impaired HRQoL [12].  Some studies have shown that patients with CHF 
experienced a poorer QoL compared to individuals with other chronic conditions 
[13, 14]. Many patients with advanced CHF also ascribe greater importance to the 
quality rather than the length of their life [15].   
The number of clinical trials incorporating HRQoL assessment as an endpoint has 
increased in recent decades [16].  Increasingly CHF clinical trials focus on the 
benefit of "add-on" therapy for which the cumulative benefits may be an 
incremental gain in HRQoL, in spite of a limited impact on survival [17].  This 
increased focus on incremental benefit means that methods of assessment and 
reporting of endpoints such as HRQoL need to be rigorous and robust. 
Although the purpose of measuring HRQoL in randomized control trials (RCTs) may 
have been to guide future patient care and treatment decisions, there is evidence 
of the limited influence of this approach on individual clinical decision making 
and/or treatment policies [18].  This may be attributed to inadequate reporting, low 
compliance with completing study measures, underpowered studies and variable 
quality in studies assessing HRQoL [19-21].  Furthermore, most clinical trials using 
HRQoL as an endpoint solely report psychometric properties and do not extend to 
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the issue of relevance of the measure nor to the rigor in measuring and reporting 
[22].  In spite of mushrooming of HRQoL assessment and as a consequence 
numerous reviews and meta-analyses on HRQoL in patients with CHF [16, 23-25]  
the methodological and reporting rigor of the HRQoL assessment in RCTs has not 
been described.  
3.3 Problem statement 
The purpose of this review was to assess the methodological and reporting of 
HRQoL in RCTs of pharmacotherapy in CHF, either as a primary or secondary 
endpoint using the “Minimum Standard Checklist (MSC) for Evaluating HRQoL 
Outcomes” [20] (Table 3.1). RCTs of pharmacotherapy were chosen for a number of 
reasons; for its potential for incremental therapeutic benefit [26]; of additive 
therapies [27]; and the fact that regulatory bodies such as the Food and Drug 
Administration (FDA) in the United States (US) request HRQoL data when making 
drug approval decisions [28].  Including non-pharmacotherapy and devices trials in 
this review would require additional methodological and reporting issues to be 
considered [29, 30]. This review also sought to investigate whether the 
methodological and reporting quality of HRQoL outcomes in RCTs has improved 







Table 3.1 Level of reporting according to the Minimum Standard Checklist for evaluating Health related quality of life outcomes in 
pharmacological trials in CHF  
HRQoL issue Description 
Conceptual  
A priori hypothesis stated Assessed whether authors had a predefined HRQOL end point and/or stated 
expected changes because of the specific treatment. 
Rationale for instrument reported Assessed whether authors gave a rationale for using a specific HRQOL measure. 
  
Measurement  
Psychometric properties reportedb Assessed whether a previously validated measure was used or psychometric 
properties were reported or referenced in the article. 
Cultural validity verified Assessed whether the measure was validated for the specific study population. 
Adequacy of domains covered Assessed whether the measure covered, at least, the main HRQOL dimensions 
relevant for a generic HF population and/or according to the specific research 
 
 
HRQoL issue Description 
question. 
  
Methodology   
Instrument administration reported Assessed whether authors specified who and/or in which clinical setting the HRQOL 
instrument was administered. 
Baseline compliance reportedb Assessed whether authors reported the number of patients providing an HRQOL 
assessment before the start of treatment. 
Timing of assessment documented Assessed whether authors specified the HRQOL timing of assessment during the trial. 
Missing data documentedb Assessed whether authors gave some details on HRQOL missing data during the trial. 
  
Interpretation  
Clinical significance addressed This refers to the discussion of HRQOL data being clinically significant from a 
 
 
HRQoL issue Description 
patient’s perspective and not simply statistically significant. 
Presentation of results in general Assessed whether authors discussed the HRQOL outcomes, giving any comments 
regardless of the results (either expected or not). 
Adapted from Efficace et.al.[20]  
aWhen multiple instruments were used in a single study only one instrument had to satisfy the item in a checklist to have deemed to have met 
the health related quality of life issue for that study.  




A search of the electronic data bases Medline and EMBASE was undertaken with 
the assistance of a health librarian. The search strategy used relevant keywords and 
Medical Subject Heading (MeSH) terms including ‘heart failure’ combined with 
‘health related quality of life’, ‘pharmacological therapy’ and ‘randomized 
controlled trials’ restricted to articles in English (See Appendix).  The search was 
restricted to 1990–2009 as it is in the last 20 years HRQoL has become a research 
area of interest. RCTs were considered to be eligible if HRQoL was explicitly 
designated as either primary or secondary endpoint. No restriction was set on type 
or number of HRQoL assessments in the study. Case reports, editorials, letters, 
commentaries, reviews, overviews and conference presentations were excluded 
along with cases where HRQoL assessment was included as a part of a composite 
endpoint. Studies with insufficient information regarding HRQoL assessment were 
also excluded. Potentially relevant articles were initially retrieved and if it was 
deemed appropriate the full text article were sought. Additional relevant studies 
were identified through a manual search of reference lists from previous review 
articles [16, 25]. 
The following information was extracted from included studies: Authors, main 
objective and study interventions, diagnosis, duration of the study, sample size, 
HRQoL used as primary/secondary outcome, description and type of the HRQoLs 
used and whether a power calculation was undertaken. When the primary outcome 
was not explicitly stated by the authors, it was defined as the one that was given 
prominence in the report or the outcome used for the sample size calculation.  
3.4.1 Minimum Standard Criteria 
Each RCT was evaluated according to the MSC [20] (Table 3.1).  This checklist 
facilitates a critical review and interpretation of HRQoL outcomes by addressing the 
basic and essential issues that a given trial should possess to have sound and 
reliable HRQoL outcomes in clinical trials [20]. This checklist consists of 11 items 
grouped into categories addressing basic and essential methodological and 
reporting issues related to HRQoL assessment in clinical trials: conceptual, 
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measurement, methodology, and interpretation. The items were originally selected 
from the literature by consensus of HRQoL researchers and further refined by an 
additional independent panel of 30 experts in the field of HRQoL including 
clinicians, psychologists and statisticians [20]. Summative scores of eight and over, 
including three mandatory items (baseline compliance, reporting psychometric 
properties or referencing validation article and missing data documentation) on this 
checklist were considered as 'probably robust'. Scores between five and seven or 
not including all three mandatory items were classified as 'limited' and all other 
studies were classified as 'very limited'. If more than one HRQoL instrument was 
used, the study was credited for fulfilling a particular criterion/checklist if it was 
satisfied by any one of the instruments employed. 
3.4.2 Statistical Analysis 
To examine the effect of time on the MSC total score for HRQoL outcome, a linear 
regression model was used with the MSC total score as the dependent variable and 
the time of publication as the continuous independent variable. Prior to linear 
regression modelling, correlation analysis was used between MSC total scores, the 
year of publication, the usage of HRQoL outcome (primary vs. secondary), sample 
size and the duration of the study in weeks to identify any confounding variables. In 
addition, the publication year was classified as before and after 2005 to further 
examine any changes between these two time periods.  
3.5 Results 
A total of 392 studies were retrieved. After excluding 256 articles (Figure 3.1) not 
meeting the inclusion criteria 136 studies were included in the review. Of the 136 
studies (See Appendix), 73 (53.7%) studies were published from 2000 to 2009. Most 
studies (n=112; 82.4%) used the New York Heart Association (NYHA) class to 
identify the patient group studied, with the most common grouping being NYHA II-
III (46/112; 41.1%) followed by NYHA II-IV (30/112; 26.8%). The reported duration 
of the study ranged from 1 week to 235 weeks with 54 (40.0%) studies reporting 12 




Figure 3.1 Flow diagram of study selection 
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Table 3.2 Characteristics of the studies included in the review. (n=136) 
Characteristics n (%) 
Sample size 
     ≤50 
     51 – 100 
     101 – 150 
    151 – 200 
     201 - 250 








Study Duration (in weeks)a 
     ≤12 wks 
    13 - 24 wks 
    25 - 36 wks 
    37 - 48 wks 







No. of questionnaire used per study 
     1 
     2 





aOne study did not specify time frame. 




HRQoL assessment was described as either a primary or co-primary endpoint in 19 
(14.0%) studies (Table 3.3). However in only 4 of these 19 studies (4/19; 21.1%) the 
sample size was calculated based on a HRQoL hypothesis or the adequacy of 
calculated sample size to detect clinically significant HRQoL changes was 
considered. In more than half of these studies (10/19; 52.6%) a sample size 
calculation was not reported at all and in five studies (5/19; 26.3%) the sample size 
calculation was based on the other endpoints. Six of these studies (6/19; 31.6%) 
were sub-studies of larger RCTs [31-35].  For studies where HRQoL assessment was 
a secondary endpoint, only four studies (4/117; 3.4%) considered the adequacy of a 
calculated sample size on HRQoL assessment [36-38] while 64 studies (64/117; 
54.7%) did not report on the sample size calculation at all. Of all 136 studies 
reviewed, 69 (50.7%) studies had a sample size less than 100 patients with the 





Table 3.3 Characteristics of studies with health related quality of life as a primary/co-primary endpoint. (n= 19)  
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10. Cowley 
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quality-of-life (HRQoL) in 
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angiotensin II receptor 
antagonist (losartan) vs. an 
angiotensin-converting-
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of beta blockade in patients 
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As reported in the paper (this may be the number of patients recruited, the number of patients who completed the study, or the number of patients who have completed 
health related quality of life assessments). 
b





Although most of studies in this review used a single measure of HRQoL (n= 103; 
75.7%), the number of instruments used in a single study ranged from one to five. 
In cases where multiple measures were used, the most common combination 
consisted of a condition specific measure and generic measure (9/21, 42.9%). The 
most commonly used HRQoL measure in CHF trials has been the Minnesota Living 
With Heart Failure Questionnaire (MLWHF) (n=83 studies) followed by a generic 
measure, Global assessment (n=31 studies where 26 studies were patient provided 
and 5 studies were provider assessed). In five studies where global assessment was 
provided by the physician three of these studies also included patient provided 
HRQoL. The only utility focused measure used in studies in this review was the EQ-
5D (n=6). The results from discrete domains of an instrument were reported in 26 
studies (19.1%). Similarly in 33 (24.2%) studies where multiple instruments have 
been used, results from individual instrument were reported. However, no study 
reported statistical adjustments for multiple comparisons. 
3.5.1 Minimum Standard Checklist 
Overall, 83 (61.0%) studies reported an a priori hypothesis or had a predefined 
HRQoL endpoint (Error! Reference source not found.). The rationale for instrument 
selection was reported in 34 (25.0%) studies.  Eighty-six (63.2%) studies provided 
psychometric properties of the instrument used or cited the validation study. 
Interestingly, although 12 (8.8%) studies stated that the HRQoL instrument was 
developed for the purpose of their study, none of these studies reported the 
psychometric properties of the instrument or cited the source of a validation 
process. In 38 (27.9%) studies it was unclear whether the instrument was 
developed for the study or the authors were using an already established 
instrument.  
While only 55 (40.4%) studies specified who and/or in which clinical setting the 
HRQoL instrument was administered, most of the studies (n=130; 95.6%) 
documented the timing of HRQoL assessment. Although 107 (78.7%) studies 
discussed the general result of HRQoL outcome in their discussion, only 57 (41.9%) 
studies addressed the clinical significance of the HRQoL outcomes. Only 23 (16.9%) 
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studies satisfied all three mandatory items of MSC. According to the MSC, 26 
(19.1%) studies were considered ‘very limited’ in methodological and reporting of 
HRQoL results and 91 (66.9%) studies were evaluated as ‘limited’. Only 19 (14.0%) 
studies were considered to be ‘probably robust’. Table 3.4 Level of reporting a 
according to the (adapted) b MSC for evaluating HRQoL outcomes in CHF 





Table 3.4 Level of reporting according to the (adapted) MSC for evaluating HRQoL outcomes in CHF pharmacological trials by the duration of study period and by use of 
of HRQoL endpoint 
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MSC Standard Checklist 1990 - 2004 
(n=89) 









Instrument administration reported 
Baseline compliance reported 
Timing of assessment documented 



























Clinical significance addressed 























MSC Standard Checklist 1990 - 2004 
(n=89) 
































aWhen multiple instruments were used in a single study only one instrument had to satisfy the item in a checklist to have deemed to have met the HRQoL 
issue for that study.  
bAn issue relating to ‘Cultural validity verified’ on the checklist has been omitted. 
cIncluding three mandatory items; baseline compliance reported, missing data and psychometric properties documented or referenced. 
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Correlation analysis demonstrated that no confounding variables were present. A 
linear regression analysis showed the absence of a significant time effect on the 
MSC scores (β = 0.025; p=0.775).  The percentage of studies judged as ‘probably 
robust’ was 14.9% for those published between 2005 and 2009 and 13.5% for those 
published earlier (Error! Reference source not found.). A similar pattern was 
observed in the ‘limited’ and ‘very limited’ groups. In fact, the only MSC item that 
has improved significantly over time was ‘rationale for instrument selection’; 36.2% 
(17/47) of those studies published between 2005 and 2009 compared to 19.2% 
(17/89) of the studies published earlier provided the rationale.  
Quality of reporting on HRQoL was higher in the trials with HRQoL as a primary/co-
primary endpoint (Error! Reference source not found.). These trials were more 
likely to report an a priori hypothesis (94.7% vs. 55.6%), the clinical setting in which 
HRQoL instrument was administered (68.4% vs. 35.9%), and to discuss the clinical 
implication of the result (89.5% vs. 34.2%). According to the MSC, while 42.1% 
(8/11) of the studies with HRQoL as a primary/co-primary endpoint were 
considered ‘probably robust’, the percentage was much lower for the studies with 
HRQoL as a secondary endpoint (9.4%, 11/117). Of the studies with HRQoL as a 
primary/co-primary endpoint, the remaining 57.9% (11/19) of the studies were 
evaluated as ‘limited’ with none being ‘very limited’. However, 22.2% (26/117) of 
the studies with HRQoL as a secondary endpoint were ‘very limited’. 
3.6 Implications of this review 
Although HRQoL assessments have the potential to provide a meaningful and 
clinically relevant outcome of a disease and the effects of pharmacotherapy from 
the patient’s perspective, our analysis reveals that the methodological and 
reporting rigor of HRQoL assessment in these RCTs has been less rigorous than 
reporting standards in cancer [53]. Only 14.0% of the studies can be described as 
‘probably robust’. This compromises the value of such data.  
In some studies the researchers did not provide an operational definition of HRQoL 
and the ambiguity of those constructed has been previously noted [21]. 
Subsequently, there was no description of how the multidimensional concept of 
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HRQoL including physical, psychological and social domains was measured. In fact, 
in some studies the terms “HRQoL” and “physical functioning” and/or 
“symptoms/side effects” were used interchangeably from study question to 
methods to discussion. For example, in a study the research question may 
specifically address only one dimension of HRQoL such as physical functioning but 
in the discussion the term HRQoL would be used, or a study question may refer to 
HRQoL but only one dimension of HRQoL such as symptom burden was actually 
measured. This confusion and ambiguity has been previously reported [54].  
Although the summative HRQoL score is influenced by each domain, these domains 
in isolation do not constitute a comprehensive assessment of HRQoL. Therefore, 
extreme caution is required in drawing conclusions about HRQoL benefits when the 
assessment is based on the interpretation of results from a limited number of 
domains [19].  Furthermore, using a subset of an existing instrument may 
compromise the integrity of the psychometric properties of the original instrument 
[55].  Consequently, the use of the term HRQoL should be avoided when the study 
question only addresses one dimension of the concept or vice versa [54]. 
In this review, 61.0% of the studies stated an a priori hypothesis (or had predefined 
HRQoL endpoints) although only 25.0% provided the rationale for the choice of the 
HRQoL instrument. This is an important issue as an a priori hypothesis and the 
choice of a specific HRQoL instrument are interwoven [56].  The choice of HRQoL 
instrument in a study should be determined by the severity and nature of the 
disease as well as expected benefits and side effects of the treatment. 
Consequently, the a priori hypothesis should indicate which aspects of HRQoL are 
measures of interest and likely to be affected by the treatment under consideration 
[57].  This will ensure that an appropriate, relevant, valid and responsive instrument 
will be used for the study [58].  By reporting on these conceptual issues, the 
consumers of research can critically examine the extent to which the selected 
instrument covers the research question. 
Although more than half of the reviewed studies used an existing instrument, only 
63.2% of the studies reported psychometric properties or referenced the validation 
study. This raises a question about the validity, reliability, responsiveness, 
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sensitivity and appropriateness of the HRQoL outcomes in the remaining studies 
(36.8%). In addition neglecting to report on psychometric properties of the 
instrument may also compromise the ability to critique whether the HRQoL 
instrument is reliable and valid. In this review, 95.6% of the studies documented 
the timing of HRQoL assessment but only 40.4% of the studies reported on the 
method of HRQoL instrument administration. These issues are essential in 
interpreting study data.  
In almost half of the studies, the reported duration of the study was 12 weeks (3 
months) or less. The timing of assessment is important especially when evaluating 
an outcome such as HRQoL. In most situations, following a baseline assessment, a 
sufficient length of time may be required before HRQoL changes occur and this may 
be different from the time for clinical changes to appear. Incorrect timing of HRQoL 
assessments could potentially jeopardize the reliability and the validity of the 
HRQoL findings [59].  Erroneous findings may result due to possible confounding of 
the treatment effect on HRQoL assessment with the differential effects in 
assessment timing. If the treatment effect was measured on a HRQoL instrument 
outside an accepted time window the result may be different. Choosing appropriate 
timing of HRQoL assessment must be considered carefully to ascertain possible 
transient effects of treatment on HRQoL. 
Only 44.9% of the studies in this review documented missing data and 44.1% 
reported on baseline compliance. This is an important issue especially in studies of 
elderly patients with CHF. In such studies, patients often drop out of the study 
because of severe illness or even death. This may lead to selective loss of 
information and hence a bias may be introduced. Moreover, the most pertinent 
HRQoL results could possibly be obtained from patients who may not complete the 
trial [19].  In addition, this loss of information would reduce the sample size and/or 
information, hence the ability to detect clinically meaningful differences. 
Consequently, it is critical to provide information on strategies used to minimize 
HRQoL missing data and/or at least acknowledge how they were managed to 
increase validity of HRQoL results. This will aid interpreting HRQoL result. 
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In this review, few studies with HRQoL as a primary/co-primary endpoint reported 
sample size based on a HRQoL hypothesis or considered the adequacy of the agreed 
sample size on HRQoL assessment. In addition, almost half of the studies had a 
sample size less than 100 patients. All of these studies may have been inadequately 
powered to detect clinically important differences in HRQoL scores and this was 
acknowledged in some of the reports. It has been suggested that even when HRQoL 
assessment is a secondary endpoint and hence a power calculation is not expected, 
some a priori hypotheses should be made concerning the expected changes in 
HRQoL scores either as an effect size or minimal important differences for agreed 
sample size [19].  This assessment will assist in eliminating the disparity between 
clinical and statistical significance [58]. 
Most of the studies in this review reported on multiple HRQoL comparisons 
between different time points or/and using multiple instruments. These can 
potentially increase the proportion of missing data and false positive results caused 
by multiple comparisons without appropriate statistical adjustments [60].  
Consequently numerous approaches have been suggested to minimize this risk such 
as comparing only the summary score, adjusting p values, or to analyze only 
selected domains [19, 60].  However, all of these approaches will place limitations 
on the interpretation of the results and caution should be exercised in drawing 
conclusions from such HRQoL results. Furthermore, most of the studies did not 
specify in the a priori hypothesis whether the comparisons were made between 
treatment arms after randomization or with their respective baseline scores 
obtained at randomization. There is clearly a need for the consensus on the most 
relevant way to analyze longitudinal HRQoL data [56]. 
In a systematic review [61]  of the generic quality of life questionnaire, the Medical 
Outcome Study Short Form Health Survey, SF-36, the authors concluded that 
quality of life outcomes in clinical trials are frequently underestimated and often 
overlooked.  
Despite a dearth of information on improving methodological and reporting quality 
of HRQoL outcomes [19, 62, 63], the reporting quality of HRQoL in CHF 
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pharmacotherapy RCTs has not improved over time.  In this study this trend was 
noted in all items in MSC checklist except for ‘rationale for selecting a specific 
HRQoL questionnaire’. While few studies published before 2005 addressed this 
issue the studies published more recently showed higher compliance. This may be 
due to the US FDA requiring support for the labelling treatment benefit claim when 
making drug approval decision [64]. As expected, quality of reporting of HRQoL was 
superior in trials with HRQoL as a primary/co-primary endpoint. 
Efforts, especially in oncology, to improve HRQoL assessment and reporting in 
clinical trials have seen a major improvement [53].  The reasons suggested for this 
improvement are the development of specific guidelines and checklists for 
reviewing and facilitating the critical appraisals and interpretation of HRQoL 
outcomes [65]. A lack of familiarity regarding psychometric considerations of 
HRQoL measurement issues may contribute to inadequate reporting [53].  
Developing and adopting similar guidelines and checklists in CHF may lead to an 
improvement in reporting. 
3.6.1 Limitations of the review 
There are some potential limitations to this review. Despite the search strategy 
using two literature databases, the criteria for this review may have omitted some 
relevant and important studies especially in non-pharmacological and device trials. 
However the purpose of the study was to review the methodological and reporting 
rigor in HRQoL assessment using pharmacotherapy as an exemplar. This review did 
not take into account unpublished reports and the scarce details in some articles 
that have limited their usability in this review. Although issues addressed in terms 
of design and methods of measurement of HRQoL discussed in this review were 
limited to pharmacological trials, important HRQoL methodological issues in 
analysis, presenting and interpreting results could be applicable to other RCTs in 
CHF.  
This review did not assess the overall quality of the trial but only the 
methodological and reporting quality of HRQoL assessment in the trials. 
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Furthermore, some methodological deficiencies may lie in the reporting (or not 
reporting) rather than in their performance. In addition, this review did not 
evaluate the appropriateness or the importance of HRQoL as an outcome in clinical 
trials or the quality of the validation of the HRQoL instruments used. Although the 
MSC was developed in oncology, critical HRQoL assessment issues addressed in the 
checklist were adapted in this review for CHF. Using other criteria, the studies could 
have been categorized somewhat differently. Furthermore, by summarizing the 11 
items in MSC quality criteria into one overall score may have weighted all items as 
equally important, which may not be the case.  
3.7 Chapter summary 
This chapter has reviewed the methodological and reporting rigor of HRQoL in RCTs 
of pharmacotherapy in CHF.   
Although HRQoL is an important clinical endpoint with a potential to influence 
clinical decision making, evidence to date has shown a limited impact of HRQoL on 
patient management [18].  This may be due to clinicians’ skepticism as to the 
validity of HRQoL. To date few studies reporting HRQoL in CHF were deemed 
‘probably robust’ using validated criteria. It is important to consider that RCTs are 
perhaps the most rigorous form of research reporting and identify the best case 
scenario for reporting. Refining guidelines and checklists for the assessment of 
HRQoL outcomes in CHF clinical trials is warranted and is currently being developed 
by the Consolidated Standards of Reporting Trials (CONSORT) group [66]. The 
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The previous chapter has assessed methodological and reporting quality of HRQoL 
in CHF RCTs. The wide variations in methodological and reporting standards have 
led to difficulties in interpreting HRQoL data which in turn may have led to slow 
uptake of HRQoL in clinical practice. This thesis conceptually advances the 
discussion of PROs to discuss the issue of PIOs.  
The purpose of this chapter is to review PIO measures used in CHF and discuss 
methodological issues. The advantages and disadvantages to these outcome 
measures are included and recommendations for a comprehensive, patient centred 
outcome assessment suggested. 
Outcome measures are important in determining both the efficacy of the treatment 
and quality of care by capturing patient’s health status.  Including the patient’s 
perspective via PROs is important but it is often erroneously considered to be the 
only outcome that is important to patients. Objective measures such as mortality 
and morbidity in addition to PROs would encapsulate all dimensions of the quality 
of care and provide more comprehensive account of outcomes important to 
patients. To describe the PIOs in CHF, a structured literature review was 
undertaken. This review discusses the concepts and methodological issues related 
to measurement of PIOs in CHF. Outcome assessment at the level of the patient, 
provider and health care system is discussed in the context of PIOs. The 
perspectives of all stakeholders are considered in proposing a core outcomes set 
that is important to patients but are also meaningful and relevant to providers and 
health care system.  This core outcomes set would potentially provide a 
comparable, comprehensive and accurate assessment.  
As discussed in previous chapters, CHF is a common, complex syndrome occurring 
most commonly in the elderly [1]. CHF is often associated with limited physical, 
psychosocial and economic capacity [2, 3].  Symptom burden and lengthy, costly re-
hospitalisations are defining characteristics of the CHF trajectory [4]. People with 
CHF often have multiple medical conditions and live with debilitating symptoms 
such as fatigue and breathlessness. Therefore, the primary objective in the 
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management of CHF is to optimise patient’s wellbeing in the context of longer-term 
survival. Balancing these two perspectives is challenging and requires an 
understanding of the individual’s values and wishes, juxtaposed with those of 
health professionals and society at large.  
4.2 Outcomes 
Outcome measurement makes an important contribution to describing, 
interpreting and predicting the effects of disease and the influence of health care 
interventions [5]. Outcome assessment can be used not only to evaluate the 
efficacy of interventions but also to describe the impact of care on patients (e.g. 
patient satisfaction). Furthermore, outcome assessments support evidence-based 
clinical decision-making at the individual patient level, and identify aspects of care 
for further improvement [6]. Consequently the concept of outcomes naturally 
directs attention to the needs of patients and their well-being [7].  
Choosing inappropriate outcome measures may lead to unimportant or misleading 
information, wasted resources and a loss of opportunity to demonstrate potential 
benefits. Despite debate on perspectives of management in CHF [8-11], choosing 
which outcomes to measure from the large range available remains challenging, 
and researchers and clinicians alike require further guidance [12]. At the same time, 
as mentioned in previous chapters, there are calls from agencies such as the FDA in 
the US [13] for researchers to generate outcome models that clearly explain the 
roles and relationships between outcomes in providing an evidence base. As 
individuals live longer with chronic conditions, the burden from comorbidities 
increase and assessing the relative contributions of different conditions and 
treatments becomes increasingly complex [14].  
4.2.1 Patient important outcomes 
A growing interest in patient centred care has naturally led to seeking outcome 
measures that are important to patients[14]. Outcomes that are important to 
patients are those that patients notice, care about and for which they would be 
willing to undergo a treatment with associated risk, cost, or inconvenience for it to 
be the only thing that changed [15].  
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PIOs are outcomes that directly measures patients’ QoL [16] and/or quantity. This is 
in contrast to surrogate, substitute, or physiologic outcomes that clinicians may 
consider important. Intermediate measures such as medication adherence and 
surrogate outcomes such as improved cardiac output may be easier and quicker to 
measure. However these outcomes are not important to patients as they carry no 
meaning in improving the quality or quantity of life [17]. In contrast, outcomes such 
as symptoms, mortality and morbidity/hospitalisation would be valued. Clinicians 
and health service managers, planners and policy makers often need intermediate 
and surrogate measures to monitor progress, understand causal relationships and 
evaluate cost-effectiveness. Yet, the quality of these measures ultimately hinges on 
the strength and validity of the evidence that they are predictive of outcomes that 
are important to patients. Other terms used to indicate patient important 
outcomes include “patient oriented outcome” [18], “personal significant outcome” 
[19], “patient centred outcome” [20] and “patient focused outcome” [21]. 
4.3 Information sources and search 
Electronic databases Medline and Cumulative Index to Nursing & Allied Health 
Literature (CINAHL) were searched in addition to the World Wide Web using the 
Google Search Engine. Medical Subject Heading (MeSH) terms and keywords used 
in this search related to CHF and outcome assessment, outcome classification, 
health care outcomes and patient outcomes (see Appendix). Searches were not 
limited to any date range to enable insights into changes that may have occurred in 
outcome concepts or methods. Further additional data sources, such as clinical 
guidelines and policies were hand searched for information relevant to the review. 
The search was limited to reviews, editorials or comments on outcomes in CHF 
published in English. Methodological issues pertaining to adverse events [22] and 
burden of disease (e.g. frequency of tests, clinician assessment of disease burden) 
[23] were also identified. 
4.3.1 Data extraction and synthesis 
Data were summarised and managed using Endnote XV (Thomson Reuters, New 
York) software. Articles retrieved were analysed for discrete outcome measures 
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identified as important to patients and to discuss issues in methodological 
assessment and their relevance to patients. In addition those outcomes identified 
to be important to patients were analysed for their relevance to clinicians and 
health care systems. 
4.3.2 Eligibility criteria 
Articles were eligible if they identified outcomes important to patients in CHF and 
considered concepts and methodological issues related to measurement of these 
outcomes in CHF. 
The following questions drove the selection of articles and information.   
 What are the discrete outcomes measures identified as important to 
patients in CHF? 
 What are the measurement and methodological issues of outcome 
measures that have been identified as important to patients?  
4.4 Results 
The following numbers of references were retrieved for this review. CHF and 
outcome assessment (n=107), outcome classification (n=2), health care outcomes 
(n=4), and patient outcomes (n=65) (see Appendix).   
4.4.1 What are the discrete outcome measures identified as important to patients in 
CHF? 
Discrete outcome measures identified as being important to patients were; survival 
(mortality) [8, 9, 24-26], event free survival [24, 27, 28], hospitalisation[8, 9, 11, 20, 
29], PROs (e.g. symptoms, QoL) [9, 10, 24, 30, 31], and economic outcomes (e.g. 
cost and resource use per patient)[23, 32-34]. In addition, outcome measures such 
as mortality, morbidity as well as PROs such as symptom burden, functional status, 
psychological state, compliance with a therapeutic regimen, self-management and 
QoL are identified by the American College of Cardiology/American Heart 
Association (ACC/AHA) as important data elements for assessing the clinical 
management and outcome of patients with CHF [20]. To simplify understanding of 
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discrete outcome measures in CHF, the distinction between clinical trials and 
management has been made in their discussion. 
Mortality 
Mortality is a critical outcome measure in CHF especially when it is unexpected, 
premature, or avoidable. Unexpected death may be a result of both cardiac and 
non-cardiac causes. To be a reliable and valid outcome at the system level, 
appropriate casemix and severity adjustments need to be made to adjust for these 
differences [25].  
In CHF clinical trials, all-cause mortality has found favour as an unbiased and 
unambiguous outcome [9] and has been used as a sole primary outcome [8]. 
However as CHF care improves, mortality is becoming a less frequent event in some 
clinical trials, with the result that large sample sizes are required to detect 
differences between intervention and control groups [9]. This has led to mortality 
being included as part of a composite outcome (usually with hospitalisation). This is 
controversial because of the potential for unequal weighting of events [24]. 
The choice of all-cause versus cause-specific mortality is also contested [26]. 
Although all-cause mortality will result in a higher event rate, the inclusion of 
deaths not the result of cardiovascular disease will invariably reduce sensitivity and 
therefore power to detect an intervention effect [26]. Assessment of cause-specific 
mortality improves precision but presupposes no impact on non-cause specific 
mortality, which may not necessarily be true.  
As well as providing a clearer indication of the effects of management, cause-
specific mortality can also provide insights into a broader concept of chronic 
condition and its mechanism. However, a focus on cause-specific mortality requires 
researchers to distinguish between cardiovascular death and death caused by 
comorbidity. The difficulty of adjudicating the cause of death may depend on the 
quality of documentation provided on the death certificate, particularly for 
community based deaths [26]. Furthermore, although cause-specific mortality may 
provide clinicians and health service operatives with important information to 
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improve care and service delivery, it may not be meaningful to patients or their 
families for whom the impacts will be the same regardless of cause [26].  
Hospitalization 
Data on hospitalization (eg. cause of admission, length of stay) provides useful 
information on prognosis, allows inference regarding the burden of CHF and 
management on patients and their families, and informs cost effectiveness analysis 
[24]. Despite its utility, hospitalisation as an outcome measure has limitations.  
Admission to the hospital is  influenced by patient and social preference and 
differences in practice patterns, with thresholds determining admission and length 
of stay varying according to country, region and even institution [8]. The use of 
“observational stays” in some institutions and “short stay”[8] holding units in 
emergency departments further confounds comparison between studies. As with 
mortality, there is also the dilemma of whether to choose all-cause or cause-
specific hospitalisation, with advantages and disadvantages to each [26]. When 
adjudicating the reason for hospitalisation, the definition of CHF hospitalisation is 
likely to vary depending on severity of CHF, comorbidities and related admission 
policies [11]. Although the rigor of this metric has been widely challenged, the 
importance of hospitalisation in terms of health care system costs has maintained 
this focus. 
Patient Reported Outcomes  
As discussed previously, over the past two decades there has been a growing 
interest in collecting outcomes that are important to patients to ensure clinical care 
is patient centred [35]. Implicit in this process is obtaining the perspective of the 
patient through the use of PRO.  
As discussed in previous Chapters, PROs can be used to inform health decisions in a 
wide range of applications from individual patient decision-making through to 
developing health policy aimed at improving population health [36]. Routine 
administration of questionnaires to measure PROs can be used to screen for unmet 
needs [7] or problems such as depression and anxiety [37]. Evaluating satisfaction 
with treatment may assist providers in understanding the issues influencing 
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treatment adherence and may help identify aspects of management linked to long-
term treatment outcomes [38]. PROs can also facilitate communication amongst 
the health care team by providing a common language amongst professions from 
different clinical backgrounds [39]. Finally, established discrepancies between 
clinician and patient perceptions of symptoms and treatment effectiveness 
mandate collection of patient reported data to inform future practice [39].   
In clinical trials, PROs provide a number of advantages over and above traditional 
outcomes such as mortality. They offer a way to differentiate benefits when two or 
more treatments present with similar clinical efficacy [40]; they measure the 
benefit of "add-on" therapy that has the primary objective of providing an 
incremental benefit to QoL rather than substantial impact on survival [41]; and they 
can be used to examine long-term impacts of treatment on daily life in the context 
of lengthy survival, increasingly an issue in CHF [42].  
Issues in Patient Reported Outcomes 
PROS usually reflect unobserved (latent) concepts which may manifest themselves 
in different observable ways depending on the condition or treatment of interest. 
There is a challenge in selecting the most appropriate measure that would fulfil the 
objectives of the outcome assessment. It must also be guided by the severity and 
nature of CHF and ensure PROs measure selected would measure benefits/side 
effects of the therapy as well as the change in patients as CHF progresses. PROs are 
inherently subjective and rely on patient’s self-report [43]. This means it is also 
imperative for PROs to be reliable and valid as well as responsive and relevant [44]. 
In addition, relying on self-report means PROs data are more prone to missing data 
than other clinical outcomes [34]. This is an important issue especially in many CHF 
studies where elderly patients may often drop out due to severe illness or even 
death.  Consequently, this type of missing data may lead to bias which may result in 
an erroneous conclusion [45]. 
In evaluating PROs, the timing of the outcome assessment is crucial. In most 
situations, the timing of the assessment of PROs will depend on disease 
progression, the therapy response, the risk of premature death or adverse events 
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and the respondent burden [44]. Incorrect timing of PROs assessments could 
potentially jeopardize the reliability and the validity of the PROs findings [46] by 
biasing the treatment effect. If an evaluation of PRO measure took place outside an 
accepted time window the result may be different. In addition, choosing 
appropriate timing of PRO assessment, requires careful consideration of the 
transient effect of therapy on PROs measure. 
PRO data, especially QoL, comprise multiple components such as individual's 
perceived physical, psychological, and social well-being [47]. Statistical analyses of 
these data often result in false significant results due to multiple testing.  Several 
methods have been suggested to address the multiplicity issues such as comparing 
only the summary score, adjusting p-values, or to analyze only selected domains 
[45, 47].    
In interpreting PROs, there is a need to determine the minimal important difference 
(MID). This measure enables interpretation of outcome assessment beyond 
statistical significance. However, it can be argued a meaningful change is a 
subjective concept and it may differ depending on different perspective. There is 
clearly a need for a comprehensive interpretation strategy that incorporates 
different anchors, each having its own metric that is meaningful to a given audience 
[32]. Works have been carried out to establish MID for Minnesota Living With Heart 
Failure Questionnaire [48] and the Kansas City Cardiomyopathy Questionnaire [49], 
two most popular HRQoL measures used in CHF [50].  
Economic Cost 
With two-thirds of the economic burden of CHF accounted for by admissions to 
hospital [34], outcomes such as admission or/and readmission along with visits to 
the physicians are considered important [32]. Currently CHF patients have three 
times as many visits to the health care provider, twice the number of emergency 
visits and greater than three times more inpatient admission compared with other 
patients [51]. Subsequently, frequent admissions to hospital and visits to physicians 
would have an impact on the economic cost. At an individual level, economic cost 
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would include lost productivity as well as direct and indirect costs of care at 
personal level such as hospital transportation [33] 
Adverse Events 
An adverse event is defined as an unintended harm due to medical management or 
lack thereof in contrast to complication arising from the underlying disease [22]. 
Although adverse events may be linked with quality of care and patient safety, 
presence does not necessarily indicate poor quality, nor their absence good quality 
[22]. Most patients with CHF have one or more co-morbid condition that will 
potentially cause treatment conflict, [52] especially when multiple medicines are 
prescribed. This places patients with CHF at risk of adverse outcomes which may be 
captured by mortality, hospitalisation and PROs (eg. side effects and symptoms).  
Burden of disease 
Burden refers to the demands experienced by patients, caregivers, clinicians, the 
health care system and society [5]. Patients’ and carers’ burden can be expressed as 
mortality, hospitalisation, and PROs such as symptom burden [31]. In some 
instances economic burden is also described at an individual level. As mentioned 
above, this may include lost productivity as well as direct and indirect costs of care 
such as hospital transportation due to [33] but may also include physical and 
emotional burden especially for the elderly. Patients’ and carers’ burdens are 
usually linked with expectations of and satisfaction with care [5] as measured via 
PROs.  
The burden of CHF at a system level has generally been measured with traditional 
indices such as incidence, mortality, and morbidity and increasingly health services 
utilisation, particularly hospitalisations [53] and they may provide valuable 
information to patients. One definition of the burden of disease is a measure of the 
years of healthy life that an individual or population loses as the result of disease.   
Generic outcomes that combine both mortality and morbidity into a single index 
such as disability adjusted life years have also been used [54].  However from 
patient’s perspective these indices are not easy as easy to understand. Identifying 
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the outcomes important to patients such as QoL are important considerations in 
determining disease burden.   
4.4.2 Outcome assessment in clinical management 
In clinical management, the purposes of outcome measurement typically include 
monitoring and support of patient progress, diagnosis, treatment and 
communication [55].  Outcomes assessment in clinical management can be 
targeted at either or both of two levels: at an individual patient care level and/or at 
an aggregated system level [56]. Information at the system level can be collected 
and analysed at either the clinic or group practice level.  
In clinical management, outcome assessments typically use routine data to avoid 
undue burden on patients that may not have immediate consequences for their 
own personal care. Routine outcome data is subject to numerous biases and is 
unlikely to be of sufficient quality for rigorous evaluation of treatment efficacy [57]. 
Nonetheless, outcome data can be utilised in measuring the quality of care, 
designing system interventions, reallocating resources and research efforts, training 
health care personnel and characterising a patient population to better understand 
their needs. 
4.5 Discussion 
The current review has found a range of commentaries and reviews concerning 
outcomes measures important to patients in CHF yet no gold standard exists. While 
there was a general agreement that outcomes assessment is essential in improving 
care, a number of strengths and limitations were highlighted in each of outcome 
measures important to patients.  
Outcomes in CHF are used to describe the impact of treatment/care on patients’ 
lives. Incorporating patients’ perspective in the form of PROs means an essential 
element [58] of patient centred care is being practiced. Indeed, there has been a 
call to include PROs in routine clinical practice [41].  Therefore, choosing outcome 
measures that are meaningful to patients is essential. Traditionally patient 
outcomes in CHF have been mortality, hospitalisation and avoiding or decreasing 
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adverse events of care [10]. With debilitating symptoms including fatigue and 
breathlessness, improving functional status and HRQoL have become patient 
important outcomes. Increasingly patients’ perspective as expressed in PROs such 
as HRQoL, functionality, symptoms (and symptom management) and more recently 
quality of death have become outcomes important to patients [59].  
Increasingly, there is a recognition that patients’ desired outcomes may change as 
the patients and their carers evolve as the disease progresses and treatment/care 
becomes familiar [60]. Undoubtedly, for many patients, outcomes such as mortality 
and morbidity/hospitalisation would play a central role and override any 
consideration for other outcomes. This would be the case, especially in patients 
with mild symptoms where their prime objective would be to improve survival [61]. 
However in more severely ill patients with distressing and in times disabling 
symptoms, this may not be so; an improvement in their QoL or symptom relief may 
be more important [62]. Consequently, in examining PIOs, PROs need to be 
considered in conjunction to clinical outcomes such as mortality and 
morbidity/hospitalisation [63]. In order to consider the relevance and 
meaningfulness of these measures, it is useful to consider patient, clinician and 
system perspectives in CHF outcome assessment and these are summarized 
in.Table 4.1. 
4.5.1 Clinician level 
In providing care to patients with CHF, clinicians aim to increase survival and 
improve QoL both by managing current problems and preventing future morbidity. 
To achieve this, clinicians need to monitor the processes and results of care to 
inform future improvements to care and support shared decision-making with 
patients [64]. Process measures include patient understanding of self-management 
advice, availability of support and adherence to treatment as well as vital signs, 
laboratory and diagnostic test results, and response to medications [12].  
Physiological and elemental outcomes such as changes in pulmonary capillary 
wedge pressure and natriuretic peptide levels may be disease rather than patient-
centred but are nonetheless an important part of CHF patient management [65]. 
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They inform clinicians of the status of disease process as well as the mechanism 
related to the patient problem and a better understanding of the way a treatment 
works [65].  Intermediate outcomes should ideally require minimal additional 
resources and minimal disruption to the delivery of care. Furthermore, they should 
be clinically useful and acceptable to patients [56]. As much as possible, they should 
inform concrete action (eg. provision of information) [63] to improve patient care. 
But it is important to emphasise that these outcomes should be supportive of, 
rather than alternative to outcomes that are important to patients. 
4.5.2 System level 
At a system level, outcomes evaluate changes in health of a defined population as a 
result of health care or health system activity [66]. Outcome measures at this level 
assist in establishing and evaluating health policies that may benefit CHF 
communities.  Such methods of assessment are critical in informing policy 
decisions. As demands on resources increase, outcome measures are increasingly 
needed to enable disparities in burden to be highlighted across different health 
conditions and geographical regions as well as over time. Outcome measures have 
an important part to play in examining accessibility of quality CHF care across the 
population. These applications are needed to ensure the health care system is 




Table 4.1 Patient, clinician and system perspectives in chronic heart failure outcome assessment 
 Perspective 




 Minimize risk of CHF 
 Restore to “health” in 
timely way 
 Ability to live a normal 
life 









 Plan services 
 Monitor the quality of 
care/treatment 
provided 
 Justify cost of care 
 Improve population 
health 





 Timely access to 
quality care 
 Minimize symptom 
burden and ‘functional 
limitation 
 Survival 
 Avoid major clinical 
events such as 
hospitalization 
 Self- management of 
CHF 
 Feel safe and secure 











 Avoid adverse 
events 
 Good liaison with 






 Appropriate service 
provision 
 Improved knowledge 
and understanding of 
CHF and related risks. 








 Functional status 
 Patient satisfaction 
 
 Mortality 








 Hospital days 






Given the escalating health care cost associated with CHF and other chronic 
conditions, it is important to balance societal benefits with expenditure to allocate 
care and resources judiciously. There is a need to understand the relative benefits 
of the various treatment options for CHF in terms of clinical and economic 
outcomes. The quality adjusted life year (QALY) is widely used for economic 
evaluation across health care [67]. QALYs combine information on both quantity 
and quality of life and offer a standard unit for comparison across different 
interventions and places on the disease trajectory [68]. That said, there have been 
numerous criticisms of QALYs, especially concerning the methods used to generate 
their utility weights and the use of QALYs for informing allocation of health care 
funds between disparate conditions [30]. A broader assessment at system level 
would include cost-benefit analyses [69] and loss of productivity as possible societal 
outcomes. 
Two-thirds of the economic burden of CHF can be accounted for by admissions to 
hospital alone [34], making interventions that avoid (re)admission a priority from 
the system perspective. At the same time, there is a need to measure 
hospitalisation and other system outcomes in terms of their impact on the patient 
[70]. While we may assume that patients generally wish to avoid hospitalisation, it 
may be that this is a preferred outcome for some people who lack support in the 
community [71]. PROs such as psychological wellbeing, unmet needs and 
satisfaction with care have so far had a limited influence at the systems level. 
Future work is needed to integrate these measurements into the systems level 
model. 
4.5.3 Moving towards a prioritised, integrative model of outcomes assessment 
This chapter has considered outcome measures of importance to patients and 
considered their importance at clinician and health care systems level. Mortality, 
hospitalisation and PROs are outcomes that are relevant and important to all 
stakeholders of CHF care and have wide application in research and clinical practice. 
The outcomes are important as it facilitates decision making at all levels of care. To 
patients and healthcare purchasers outcome measures will provide information 
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about the quality of care available to them; to clinicians and healthcare systems a 
feedback on the quality of care that they provide, which in turn will enable them to 
identify areas for improvements as well as differentiate themselves from other 
institution [70]. If standardised, this “core set” of outcomes has potential to enable 
both evaluation of health care effectiveness and monitoring of population health 
[72].  
Identifying consensus in the relevance, appropriateness and importance of 
outcomes between patients, providers and health systems is important in 
generating an integrative model of health care assessment that has utility and 
relevance.   This will require a reengineering of   health care systems to shift the 
rhetoric of person-centred care to conceptual integration and relevance in systems 
and processes.  Shifting beyond tokenistic consumer representation will be 
important [73] .  
 Furthermore, as evaluation metric are often a driver of service organisation and 
delivery, having a genuinely patient centred outcome goal is likely to alter service 
provision. The critical issue is whether this should be approached by developing a 
single measure, by measuring a core set of outcomes and trying to combine the 
results as a composite outcome, or by keeping them as a set of individual 
outcomes. Although there is an argument any single outcome may not be adequate 
to capture important differences [68], comparability and interpretability of 
outcome assessment will be greatly facilitated by a simple measure of outcome [74] 
such as a composite outcome. In addition, combining multiple outcomes into a 
single summary measure is a useful approach for defining ‘net benefit’ [75].   
4.6 Chapter Summary 
Although the literature challenges conceptual and methodological assumptions of 
conventional end-point assessment methods, to date there has been limited 
application on non-traditional measures [24]. Choosing measures must depend on 
the capacity to provide comprehensive, comparable, meaningful, and accurate 
reflection of outcomes as well as the capacity for data collection. Measurement 
issues such as reliability, validity and utility in meeting the needs of a range of 
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stakeholders are important but ensuring these outcomes are important to patients 
is as or more important.  This requires a conceptual shift that requires an extension 
from PROs to PIOs. For example, for many patients with CHF, mortality is of a 
critical consideration. This is illustrated in the high uptake of left ventricular device 
as destination therapy in the US [76]. 
While it is likely that utility will vary from the perspective of patient, clinician and 
health care system, the needs of clinicians and the system should be seen as 
supportive of rather than alternative to those important to patients; a core 
outcomes set with broad-scale application and appeal.  
A strategy to encapsulate the range of perspectives as outlined in this chapter has 
been the use of composite outcomes. The next chapter will discuss methodological 
and weighting issues in composite outcomes combining set of patient important 
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As discussed in previous chapters, CHF is a common, complex and multifaceted 
syndrome [1]. Living with a life limiting illness challenges traditional outcomes such 
as mortality and morbidity in clinical trials to assess the impact of CHF and 
treatment options on patient centred outcomes particularly QoL.  Studies using 
comparative normative data the degree of physical, mental and social functioning 
impairment was greater in patients with CHF than those with other chronic diseases 
[2, 3]. Many patients with advanced heart failure ascribe greater importance to 
quality than to duration of life [4]. Subsequently, selection of outcomes in both 
clinical trials and practices should be undertaken with great care. 
In Chapter 4, outcome measures important to patients were determined and their 
usefulness at provider and health care systems level were considered. Mortality, 
hospitalisation and PROs, such as QoL were proposed as a core outcomes set 
relevant and important to all stakeholders of CHF care and explored their wide 
application in research and clinical practice. This Chapter will discuss the strengths 
and weaknesses of composite outcome assessment and proceed to test three 
established composite outcome models which incorporate a core outcomes set of 
mortality, hospitalisation and an example of PROs, QoL [5-7].  
Beyond conceptual discussion, measurement issues were described through 
undertaking a secondary analysis of a prospective, multi-centred RCT of 280 
hospitalized CHF patients in the Which Heart failure Intervention is most Cost-
effective & Consumer Friendly in Reducing Hospital Care? (WHICH(?)) Trial [8].  
These data were used to compare and contrast three composite outcomes that 
comprise mortality, hospitalisation and QoL in CHF to understand the influence of 
each component to the final outcome. 
5.2 Outcome measurement in clinical trials 
Exploring different outcomes in CHF and cardiovascular clinical trials have 
demonstrated the lack of consensus on appropriate measures [9-11]. In some CHF 
clinical trials, there is a recognition that treatment efficacy needs to be measured 
by multiple outcomes, especially where management or the outcomes of 
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interventions have multiple components [12]. A composite outcome in a clinical 
trial is where clinically relevant outcomes are combined into a single outcome that 
can characterize clinically meaningful benefits of a treatment [13].  
5.3 Composite outcome 
Essentially there are three types of composite outcomes. The first type is a total 
score which effectively combines signs and symptoms of a disease [14]. The second 
type of composite outcome is an ‘event’ rate after a certain period has elapsed 
since treatment [14]. The third type of composite outcome is defined as the time to 
the first ‘event’. In both the second and third type of composite outcomes the 
definition of ‘event’ is pre-specified clinically relevant and meaningful event 
amongst several possible event types [14].  
5.3.1 Issues in composite outcome 
Using a composite outcome requires considerations, such as the selection of the 
number and type of clinical relevant components, to include in a composite as well 
as the interpretability of such an outcome [11]. The number of components in a 
composite outcome and their relative weightings have important implications in 
the interpretation of the composite outcome [11]. In CHF trials, the composite of 
mortality and hospitalization has become the standard primary outcome for 
regulatory trials [17] with or without worsening HF. The strengths and weaknesses 
of such an approach have been widely debated and discussed [13]. 
5.3.2 Strength of composite outcome 
Composite outcomes are useful both for capturing multiple components and 
additive effects of interventions and also for reducing sample size due to increased 
event capture. These approaches to outcome assessment are usually considered 
when no single end point can accurately capture the totality of the patient 
experience [15]. The benefits of such an approach include a reduced sample size 
and cost of undertaking a trial, and the ability to capture the net benefit of the 
intervention [16]. These benefits have led to increased use of composite outcomes 
in clinical trials.  
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Combining multiple outcomes into a single summary measure will undoubtedly 
define ‘net benefit’ [16].  Using a composite outcome will circumvent the need to 
make an allocation for multiple hypotheses testing, as one is essentially dealing 
with a single outcome [14, 17]. In addition, the problem of competing risks can be 
avoided especially if a clinical outcome such as mortality, is combined with 
morbidity [15]. Ultimately, the composite outcome derived from mortality, 
hospitalisation and QOL would lead to greater efficiency and higher quality of care 
by incorporating the clinical effectiveness at the individual patient level and 
economic costs as expressed in hospitalisation at the population or policy level.  
5.3.3 Weakness of composite outcomes 
Composite outcomes are difficult to interpret when the treatment effects vary 
considerably across the components of the measure. The most extreme case would 
be when the components are moving in different directions such as an increase in 
mortality and an improvement in QoL. The problem of interpretation is 
compounded when components are dissimilar in patient importance [18]. Many of 
these problems may be resolved by choosing clinically relevant components of the 
composite and applying appropriate weightings of these components [11, 18]. Yet 
there is limited discussion on the selection of components as well as derivation 
method of composite outcomes or in establishing the standards for weighting 
components of a composite outcome. 
5.4 Objective 
The study presented in this chapter was designed to provide a better understanding 
of measurement issues in composite outcome assessment. Examples of composite 
outcomes incorporating mortality, hospitalisation and QoL in CHF management 
were examined in data derived from a pragmatic trial comparing multidisciplinary 
CHF management delivered via an outreach, home-based intervention (HBI) or 
outpatient, specialised CHF clinic-based intervention (CBI) [8]. Three commonly 
known composite outcome models were selected. These are Packer’s ordinal 
composite score (improved, unchanged or worse)[6], Cleland’s Patient Journey [5] 
and composite outcome used in the African American Heart Failure Trial (A-HeFT) 
[7]. Each of these composite outcomes incorporates all-cause mortality, 
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hospitalisation and QoL albeit using different derivation method and/or different 
weighting of the components.  
The main objective of this analysis was to compare these three composite 
outcomes to increase the understanding of the numerous pathways that 
components influence the final outcome in CHF patients. Specifically, three 
composite outcomes were compared and contrasted using the same data from a 
prospective trial of community CHF management [8]. The rationale for the choice of 
this data set was to capture the perspective of living with CHF. Moreover, this data 
set was more likely to have captured the perspective of the ‘real’ world of CHF, 
rather than a highly selected clinical trial population [19]. 
 All components in the composite were examined separately to estimate their 
relative effect on respective composite outcome. An association between each 
component (ie. mortality, hospitalisation and QoL) to their respective composite 
outcomes will be examined.  
This analysis did not seek to assess which composite outcome is the ‘best’ nor to 
assess the validity of these composite outcomes but rather to try to gain insight 
into the relationship among composite outcomes that measures similar 
component, namely mortality, hospitalisation and QoL. In addition, using Packer’s 
score [6], the Patient Journey [5] and A-HeFT composite outcome [7] we sought to 
examine the methodological consequence of each component on the final 
outcomes. 
5.4.1 Packer’s composite outcome 
The Packer’s composite outcome was first introduced by Packer in 2001[6]. This 
score combines mortality, heart failure hospitalisation, change in NYHA 
classification and a change in patient’s global self-assessment of QoL, to classify 
patient as improved, unchanged, or worsened (Table 5.1. ) Amongst three 
composite outcomes examined in this study, this composite outcome is perhaps 
most widely used in clinical trials. The Packer score has been used in the predictors 
of response to cardiac resynchronisation (PROSPECT) study[20], and the 
resynchronisation reverses remodelling in systolic left ventricular dysfunction 
(REVERSE)[21] to name a few (Table 5.1). 
 
 
Table 5.1 Packer’s composite, Patent Journey, and A-HeFT composite 
Component Packer’s composite Patient Journey A-HeFT composite 
Mortality All-cause mortality expressed as an 
indicator variable (N=0, Y=1) 
Days dead: The number of days 
from all-cause mortality to the 
end of study. 
 
All-cause mortality expressed as 
an indicator variable (N=0, Y=1) 
Hospitalisation First HF Hospitalisation expressed as 
an indicator variable (N=0, Y=1) 
Days in hospital: Total time in 
hospital for all causes 
Add the durations of all individual 
hospital stay 
  
First HF Hospitalisation expressed 
as an indicator variable (N=0, Y=1) 
Quality of Life Change in patient global assessment 
and change in NYHA functional class 
Average NYHA functional class 
over the duration of the study 
moderated by the increased use 
of diuretics 
Change in MLWHFQ from 
baseline to follow-up.  
Derivation method 
 
Patients are classified as worse, 
same or better as: 
Initially, Days Alive and Out of 
Hospital (DAOH) will be 
calculated. The patient journey 
This composite outcome consists 
of composite score of weighted 
values of all-cause mortality, first 
 
 
Component Packer’s composite Patient Journey A-HeFT composite 
Worse  
Experienced death or HF 
hospitalisation during the planned 
duration of treatment or reported 
worsening of their NYHA class* or 
global assessment by at least one 
class at the final visit compared to 
the baseline. 
Same  
Neither improved nor worse (ie. 
Did not experience death or HF 
hospitalisation and no change in 
patient global assessment of QoL 
or NYHA class) 
Better 
Experienced a favorable change in 
NYHA class or in the patient global 
incorporated a patient's 
functional status by allocating 
each day of the DAOH to the last 
known NYHA status of the patient 
for that day. 
 Calculation of DAOH: 
Total days in the study: number 
of days from randomization until 
the date of the final patient 
examination (if alive) or end of 
study. 
DAOH = Total days in the study – 
(days dead + days in hospital) 
 
Apply the following score 
weightings as reported in the 
COMET trial to the various 
HF hospitalisation and change in 
QoL score using MLWHFQ. 
 
Scoring scheme 
 All cause death (at any time 
during the trial)   (-3 points)         
 First (HF) hospitalisation 
(adjudicated) (-1 point) 
 Change in quality of life  
 Improvement by 10 units or 
more  (2 points) 
 Improvement by 5-9 units (1 
point) 
 Change by <5 units (0 point) 
 Worsening by 5-9 units (-1 
point) 
 Worsening by 10 units or 




Component Packer’s composite Patient Journey A-HeFT composite 
assessment by at least one class 
from the baseline but did not 
experience death or HF 





NYHA class                     Weight 
I                                  1.00 
II                                 0.86 
III                                0.76 
IV                                0.60 




0 - Total Potential follow up days -6 to 2 
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5.4.2 Patient Journey 
The Patient Journey is another composite outcome in CHF that incorporates 
information on mortality, hospitalisation and QoL. It also includes the change in 
therapy in the scoring scheme in this composite outcome [5]. Essentially this 
measure is a refinement of days alive and out of hospital (DAOH). It incorporates 
longevity and out of hospitalisation into a single measure in days, and weighting 
them using the patient’s QoL as measured with the question “How have you been 
feeling over the past week?” with a five-point scale from very good to very poor [5]. 
This five point score is then converted to a value between 0 and 1 which 
subsequently is applied to DAOH (Table 5.1). The intensification of diuretic therapy 
to control symptoms is also integrated by assuming patients to be one class worse 
in the patient QoL  than actually expressed, unless the patient is already in the 
worst class [5]. In this metric a reduction in diuretic therapy is not considered to 
have led to improvement in QoL.  
5.4.3 African American Heart Failure Trial composite outcome 
The A-HeFT composite outcome is designed to consider all-cause mortality, a first 
HF hospitalisation, and a change in QoL using MLWHFQ. A weight given to each 
component to generate the composite is shown in Table 5.1. Initial score assigned 
to all patients is 0, which will change depending on patient’s experience;  death at 
any time, counted as -3, a first hospitalization from HF -1 and a change in QoL 
varying from -2 to 2 depending on the degree of improvement or worsening of QoL 
(Table 5.1). This composite outcome only considers the event of the first HF 
hospitalisation and not the total number of HF hospitalisations. Hence the A-HeFT 
composite outcome focuses on the change from baseline status rather than an 
absolute number of events [7]. Interestingly, this composite outcome assigns 
greater values for some changes in QoL than for first HF hospitalisation. 
5.4.4 Scoring 
The scoring algorithms for each of the components for the composite outcomes are 
summarised in Table 5.1. Each component was considered alongside the most 
comparable components. Despite comparable components measure similar 
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concepts they capture and score them differently. This was especially evident in 
Patient’s Journey, which is weighted DAOH, hence the final outcome is in days. The 
first step in the Packer’s score and A-HeFT composite is to express death and first 
HF hospitalisation information as an indicator variable (0, 1). The extent of 
difference in measuring and scoring scheme for each component are apparent even 
in hospitalisation component; for Packer’s and A-HeFT score, component to be 
incorporated was HF hospitalisation whereas for Patient Journey, it was all cause 
hospitalisation. For QoL component, not all composite outcomes use the same 
instruments and in some cases more than one measure are used to capture QoL. In 
Packer’s composite score, change in NYHA functional class is combined with 
information on the changes in patient’s QoL, while in Patient’s Journey, information 
on increased use in diuretic is used to adjust QoL weights to be applied to DAOH. 
5.5 Method 
Data used in this study came from the WHICH(?) a multicentre RCT [8].  Briefly a 
detailed description of the rationale and design, baseline findings and primary 
results is provided [8, 22].   
The main focus of the study was to compare the multidisciplinary CHF management 
delivered via an outreach, HBI with an outpatient or a CHF specialised CBI. The 
inclusion criteria included the moderate to severe symptoms of HF with NYHA 
functional class II-III with at least one admission for acute heart failure. A total of 
280 patients were recruited from three tertiary referral hospitals in three different 
states in Australia.   
5.5.1 Study Data  
Detailed demographic and clinical data were collected at baseline (see Table 5.2 for 
indicative profiling in a standardized manner by trained personnel). All surviving 
patients were subject to clinical follow-up at 6 months (brief telephone call), 12 
months and a final  follow-up up to 18 months (pre-scheduled home or clinic visit).  
5.5.2 Post-Discharge Management  
The key components and principles of post-discharge management of CHF, either 
delivered as an outreach, HBI or via a CBI coordinated via a specialist CHF 
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outpatient clinic, according to best practice guidelines. The Australian health care 
system provides universal health care for the population with only minimal costs 
(capped for those with chronic disease) for hospital treatment, pharmacotherapy 
and community care (including family physicians). The study was designed to 
standardize the elements of care (often supported by the same cardiologists and 
general practitioners).  
5.5.3 Study Design 
Briefly, HBI patients were scheduled to receive a home visit by a trained CHF nurse 
within 7-14 days of hospital discharge. This comprised a structured and detailed 
assessment of the patient’s clinical stability, application of gold-standard 
pharmacological and non-pharmacological management and any factors likely to 
positively or negatively impact future health outcomes. Subsequently, a report was 
sent to the patient’s family physician and cardiologist and planned management 
(including telephone follow-up, referral to other health care professionals and 
additional home visits) was arranged. Regardless of initial assessment, those 
discharged to home following an unplanned hospitalization were subject to re-
evaluation of the relative success/failure of management by the CHF nurse. 
Similarly, CBI patients were scheduled to attend a post-discharge visit to the nurse-
led specialist CHF clinic where they had access to a multidisciplinary team. The 
same principles of assessment and follow-up as per HBI were applied. The key 
differences being that for the CBI group: a) management was primarily directed 
through the specialist CHF clinic on an outpatient basis and b) they did not receive a 
comprehensive home visit. No restrictions on access to other health care services 
were applied. 
5.5.4 Baseline characteristics 
Of these, 143 patients were randomized to the home-based and 137 to clinic-based 
post-discharge management. As previously described [8], baseline characteristics 
were similar in the 2 groups. All hospitalisations were adjudicated on the type 
(elective/unplanned) and the causes and all death were reviewed by a blinded 
outcome committee.   
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Demographic Profile  
 Men 203 (73) 104 (73) 99 (72) p=0.931 
 Age at entry (years)  71 ± 14 70 ± 15 73 ± 13 p=0.046 
 Living alone    155 (55) 80 (56) 75 (55) p=0.746 
 Less than 12 years education  54 (19) 32 (22) 22 (16) p=0.520 
Risk Factor Profile  
 Hypertension  177 (63) 93 (65) 84 (61) p=0.519 
 History of Smoking 194 (69) 97 (68) 97 (71) p=0.590 
 BMI (kg/m2)  28.3 ± 6.9 28.6 ± 7.8 28.0 ± 5.8 p=0.537 
 Total cholesterol (mmol/L)  3.9 ± 1.3 4.0 ± 1.3 3.9 ± 1.3 p=0.765 
 Type 2 diabetes mellitus 109 (39) 51 (36) 58 (42) p=0.252 
CHF profile  
 Months since CHF diagnosis 39.6 ± 63.7 34.6 ± 55.3 44.8 ± 71.0 p=0.200 
 LVEF  30.1 ± 9.2 30.2 ± 9.8 30.0 ± 8.4 p=0.865 
 Preserved LV function 75 (27) 35 (24) 40 (29) p=0.534 
 NYHA Class II/III 238 (85) 118 (83) 120 (88) p=0.235 
 Ischaemic cardiomyopathy 159 (57) 78 (55) 81 (59) p=0.257 
 Prior CHF admission (1 year) 162 (58) 85 (59) 77 (56) p=0.584 
Index Admission  
 Principal diagnosis of CHF  185 (66) 101 (71) 84 (61) p=0.100 
 Length of stay (days) 8.9 ± 7.8 8.2 ± 7.4 9.5 ± 8.1 p=0.169 
 Coronary care unit (days)  4.9 ± 7.0 5.4 ± 7.3 4.4 ± 6.6 p=0.419 
Clinical Profile  
 Acute heart failure  134 (48) 69 (48) 65 (47) p=0.146 
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5.5.5 Primary Result from WHICH(?) study [22] 
In the WHICH trial 102/143 (71%) HBI versus 104/137 (76%) CBI patients 
experienced the primary outcome of all-cause hospitalization or death in 12-18 
months follow-up (adjusted HR 0.97; 95% CI 0.73-1.30; p=0.861): 96 (67.1%) HBI 
versus 95 (69.3%) CBI patients had an unplanned hospitalization (p=0.887) and 31 
(21.7%) versus 38 (27.7%) died (p=0.252). Median duration of each unplanned 
hospitalization was significantly less in the HBI group (4.0 [IQR 2.0-7.0] vs. 6.0 [IQR 
 
Systolic blood pressure 
(mmHg) 116 ± 22 117 ± 23 116 ± 21 
p=0.883 
 
Diastolic blood pressure 
(mmHg)  66 ± 12 66 ± 12 67 ± 12 
p=0.602 
 Heart rate (bpm) 73 ± 12 74 ± 12 73 ± 13 p=0.436 
 e-GFR (ml/min/1.732)  58.1 ± 23.0 58.8 ± 23.2 57.3 ± 22.9 p=0.708 
 Hemoglobin (g/dl)  12.8 ± 1.9 12.9 ± 2.0 12.8 ± 1.8 p=0.928 
 Coronary artery disease 159 (57) 78 (55) 81 (59) p=0.257 
 Atrial fibrillation 172 (61) 83 (58) 89 (65) p=0.143 
 Co-morbidity Score*   6.2 ± 2.4 5.9 ± 2.5 6.5 ± 2.3 p=0.055 
 Mild cognitive impairment  112 (40) 56 (39) 56 (41) p=0.695 
 Depressive symptom 98 (35) 57 (40) 41 (30) p=0.082 
Pharmacotherapy  
 ACE inhibitors or ARBs  213(76) 110 (77) 103 (75) p=0.632 
 Beta blockers  200 (71) 104 (73) 96 (70) p=0.626 
 Spironolactone  109 (39) 55 (38) 54 (39) p=0.870 
 Loop diuretic   232 (83) 116 (81) 116 (85) p=0.627 
 Digoxin  90 (32) 44 (31) 46 (34) p=0.615 
Legend:  BMI, body mass index (n=246); e-GFR, estimated glomerular filtration rate; 
ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker. Education 
status (n=275), lipid profile (n=119), time of CHF diagnosis (n=254) and cognitive 
impairment (n=269 cases). *Charlson Index of Comorbidity Score 
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3.5-13] days; p=0.004). Overall, 75% of all hospitalization was attributable to 64 
(23%) patients: comprising 43 (67%) CBI patients (adjusted OR 2.55, 95% CI 1.37-
4.73; p=0.003). HBI was associated with significantly less days of all-cause 
hospitalization (-35%; p=0.003) and for cardiovascular causes (-37%; p=0.025) but 
not for CHF (-24%; p=0.218). Consequently, health care costs ($AU3.93 vs. $AU5.53 
million) were significantly less for the HBI group (median $AU34 [IQR 13-81] vs. 
$AU41 [13-107] per day; p=0.030). 
5.5.6 Analysis on the composite outcome 
Initial analyses were carried out to compare the multidisciplinary CHF management 
delivered via an outreach and the HBI with an outpatient, CHF specialised CBI on 
three above mentioned composite outcomes. To ensure all patients had an equal 
follow-up duration, patients with follow-up greater than 12 months were censored 
at the date of contact at 12 months. This was necessary for Patient Journey 
composite outcome where equivalent follow-up duration was required for all 280 
patients. Subsequently, to gain insight into the relationship among composite 
outcomes that measures similar components, namely mortality, hospitalisation and 
QoL, information on patients from CBI and HBI were combined.  
Estimated Packer’s score 
All-cause mortality and hospitalisation for worsening HF were examined as an 
indicative variable during the course of 12 months follow up. If a patient died or 
was hospitalised due to worsening heart failure, they were placed in “worse” group. 
Patients were judged to have improved if they had not experienced death or HF 
hospitalisation and had demonstrated improvement in NYHA functional class or 
QoL at 12 months follow-up.  
The change in NYHA functional class from baseline to 12 months follow-up was 
assessed. If no final follow-up NYHA functional class was reported, the patient was 
assumed to be in the same state as at baseline. In this study, the result from heart 
failure specific QoL instrument, MLWHFQ was used to derive patient global 
assessment. The MLWHFQ is most widely used heart failure specific instrument 
with an excellent psychometric properties [23]. This is a self-administered 
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instrument consisting of 21 questions on patients’ perception of the effects of heart 
failure and its treatment. The questionnaire focuses on the physical, socioeconomic 
and psychological aspects of QoL, with a response format ranging from 0 to 5 for 
each question. The total score ranges from 0 to 105, with higher scores indicating a 
poorer QoL[24]. Using MLWHFQ instead of global patient QoL score for Packer’s 
composite, more specific and sensitive measures of QoL would be included in the 
Packer’s score.  
In WHICH(?) trial [8], MLWHFQ was administered at baseline, 6, 12, and 18 months. 
However for the purpose of this study, a changed score for MLWHFQ was obtained 
by subtracting 12 month follow up from baseline scores. Any missing value for 
MLWHFQ was replaced with last observation carried forward. A change of 5 points 
in the MLWHFQ is considered MID [25]. Subsequently, one class change in patient’s 
global QoL was considered equivalent to 5 point change in MLWHFQ. 
In Packer’s score, patients who have not been classified as worse or improved were 
classified as unchanged (Table 5.1). 
Estimated Cleland’s Patient Journey 
To derive Patient Journey, it is essential first to calculate DAOH. For each patient in 
the study, the total potential follow-up duration was determined as total number of 
days between baseline to 12 month follow-up. To obtain total days in hospital, the 
summation of the duration of each individual all-cause hospitalisation were 
calculated. In a case where the patient died, the number of days from their death to 
the end of the study was calculated as days lost due to death. Total days in hospital 
and days lost to death were then subtracted from total potential follow-up days to 
obtain DAOH. Patient Journey was constructed by applying Australian derived 
EuroQuol 5D (EQ-5D) indices [26] to DAOH.  
The EQ-5D instrument [27] is a widely used generic measure of QoL consisting of 
five dimensions, mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression with each having three levels. The EQ-5D has been shown to 
have satisfactory validity and reliability as an outcome measure in the 
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cardiovascular area [28, 29].The main advantage of EQ-5D is that it can be used to 
generate a single index value or utility measure [27]. In addition, in recent times, 
weights for 243 health states in EQ-5D has been derived for Australian population 
[26]. For the purpose of derivation of Patient’s Journey, instead of using the weights 
derived from discrete five point patient’s QoL scales, Australian derived preference 
measures of EQ-5D index were used. This eliminates the need to translate how 
patients feel into a utility measure [26]. It is expected EQ-5D would provide better 
utility indices than weights applied to patient global QoL [30].  
In the trial [8], EQ-5D indices were reported at baseline, 6, 12 and 18 months but 
indices at baseline, 6 and 12 months were only used to calculate the mean over the 
12 months follow-up. This calculated mean for EQ-5D indices were then adjusted 
for increase in diuretics use before being applied to DAOH. 
African American Heart Failure Trial composite outcome 
This composite outcome is made up of weighted values for death from any cause, a 
first heart failure hospitalisation during the 12 months follow-up period and a 
change in the HF specific QoL at 12 months. Original A-HeFT scores [7] assessed 
changes in the QoL at six months. However for the purpose of this study, 12 months 
was chosen as it represents the minimum follow-up period and all components for 
the selected composite outcomes are assessed at 12 months follow-up (Table 5.1). 
Methods used to derive all-cause mortality, first heart failure hospitalisation and a 
change in MLWHFQ is similar to Packer’s score. All-cause mortality and first 
hospitalisation due to worsening HF were examined as an indicator variable 
(0=no/1=yes) albeit in A-HeFT composite outcome death at any time acquires -3 
and a first hospitalization from HF -1. The changes in MLWHFQ scores were 
assigned from -2 to 2 depending on the degree of improvement or worsening of 
QoL (Table 5.1). Although the derivation method appears to be similar to the 
Packer’s composite, the major difference is that all patients are assigned a numeric 
value rather than qualitative outcome as in Packer’s score [31]. 
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5.5.7 Statistical analysis 
Descriptive analysis in the form of counts (and percentage) for each components of 
the composite for nominal data and the mean, median and inter quartile range 
(IQR) for scale measures were found. Using the data from WHICH(?) study [8] the 
final weights (or percentage) assigned to each component (mortality, 
hospitalisation and QoL) to the total score were examined for all three composite 
outcomes to provide an understanding of the magnitude of the influence each 
components has on the final composite outcome.  
Assessment of difference between study assignment 
To assess the difference between HBI and CBI, a Mann-Whitney nonparametric test 
was used for A-HeFT scores and Patient Journey and their components due to non-
normality of both composite scores and their components. For Packer’s score, chi-
square test was used. To compare the difference in study assignment for the 
Packer’s score and unweighted A-HeFT score, all-cause mortality and hospitalisation 
were analysed using Cox proportional-hazards regression  
Association between composite outcomes 
The association between the composite outcomes were assessed by Spearman’s 
rho (ρ) and for ordinal measures of association, Goodman Kruskal’s Gamma (γ)[32] 
was used. To further analyse the relationship between A-HeFT and Packer’s score a 
Kruskall-Wallis nonparametric test was used. In addition to assist in assessing 
association, Patient’s Journey as expressed as days lost was found for each category 
of Packer’s score and for A-HeFT scores. All data analyses were performed with 
Statistical Package for Social Sciences (SPSS) for Windows version 19.0 (SPSS Inc, 
Chicago, Illinois). 
5.6 Result 
In 12 months follow-up, a total of 57 (57/280; 20.4%) deaths were recorded. Of 
these, 46 patients (46/57; 80.7%) had at least one unplanned hospitalisation where 
39 (39/57; 68.4%) were for worsening HF. A total of 200 (71.4%) patients had (all 
cause) hospitalisation with 120 (60.0%) having multiple hospitalisation resulting in a 
total of 3,715 hospital days. 111 (39.6%) patients were hospitalised due to 
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worsening heart failure, resulting in 1,568 hospital days (Table 5.3). The mean 
duration of hospital stay for HF was 14.1 days (sd=15.1, median=9.0, IQR=15.0). 
Using NYHA functional class, only 8 (2.9%) patients have deteriorated over 12 
months follow-up, while 98 (35.0%) patients improved. Most common NYHA 
functional class over 12 months follow-up was class III (n=189; 67.5%). The mean 
EQ-5D index was 0.70 (sd=0.19). Changes in QoL from baseline to 12 months follow-
up were assessed using MLWHFQ where 51 (18.2%) patients indicated their 
condition have deteriorated, while 124 (44.3%) have improved in their condition. 
An increase in diuretics use usually indicates a worsening symptoms or signs of HF 
[5]. In this cohort, 29 (10.4%) patients required increase in diuretic therapy. 
Table 5.3. Component outcome characteristics in 12 months follow-up (n=280) 
Component outcome n (%) 
All cause death 57 (20.4) 
Hospitalisation  
   All cause 
     1 hospitalisation 
     > 1 hospitalisation 






   Unplanned 
     1 hospitalisation 
      > 1 hospitalisation 






   Hospitalisation due worsening HF 
     1 hospitalisation 
     > 1 hospitalisation 






Change in Minnesota Living with Heart Failure score  9.2 (1.0;22.4) 
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Component outcome n (%) 
(Baseline – Follow-up)  - Mean (SD)* 
      Improvement by 10 units or more   104 (37.1) 
      Improvement by 5-9 units  20 (7.1) 
      Change by <5 units  103 (37.1) 
     Worsening by 5-9 units  7 (2.5) 
     Worsening by 10 units or more  44 (15.7) 
Change in the New York Heart Association functional class  
     Improved by two class 19 (6.8) 
     Improved by one class 79 (28.2) 
     Same 174 (62.1) 
     Worsened by one class 8 (2.9) 
Change in diuretic use  
    Increase 29 (10.4) 
    Same 221 (79.0) 
    Decrease 30 (10.7) 
*+ve value indicates improvement 
5.6.1 Estimated Packer’s composite outcome 
The reasons for patients to be placed in worsened, improved, or same category are 
listed in Table 5.4. Of the 86 (30.7%) patients classified as improved, 44 (44/86; 
51.2%) patients improved in both NYHA functional class as well as in patient 
assessment of QoL, suggesting that there is a moderate agreement between patient 
assessment of their QoL and NYHA functional class as assessed by clinicians (Table 
5.4). More patients were classified as improved from changes in patient assessment 
than from NYHA functional class (36.0% Vs 12.8%), indicating patient assessment 
may have been more sensitive in determining patient’s QoL. 30 (10.7%) patients 




Table 5.4. Packer’s composite response details (n=280) 
Composite response details n (%) 
Worsened 164 (58.6) 
      Death 18 (11.0) 
      Hospitalisation due worsening HF 111 (67.7) 
      Worsened patient assessment or NYHA functional class 35 (21.3) 
Unchanged 30(10.7) 
Improved 86 (30.7) 
      Improved on patient assessment and NYHA functional class  44 (51.2) 
      Improved NYHA functional class only  11 (12.8) 
      Improved patient assessment only  31 (36.0) 
Of 280 patients, 164 (58.6%) worsened in their composite outcome at 1 year follow-
up. The most common reason for being classified in worse category was HF 
hospitalisation (111/164; 67.7%), followed by worsening in patient QoL assessment 
or NYHA functional class (35/164; 21.3%). Only 18 (18/164; 11.0%) patients were 
classified in worse category due to death.  Interestingly, amongst those who have 
been hospitalised during 12 months and hence classified into worse class, 46 
(46/111; 41.4% ) patients have reported  improvement in their QoL/NYHA 
functional class.  
5.6.2 Estimated Patient Journey 
Overall, patients lost 40.94% of days of life (41,676 days) from mortality, 
hospitalisation, QoL measure and a change in diuretic therapy (Table 5.5). The 
largest proportion of days lost was from limited QoL (24,867 days; 59.7% of the 
total days lost) followed by mortality (12,354 days; 29.6% of the total days lost). 
 
129 
Other reasons for days lost include all-cause hospitalisation (3,715; 8.9% of the total 
days lost) and adjustment for increased use in diuretics (740 days; 1.8% of the total 
days lost). Patient Journey, only assesses deteriorating condition as it is assumed all 
CHF patients have symptoms that impacts on their lives [5]. In this study, 71 (25.4%) 
patients were not hospitalised nor died hence only loss of days were due to limited 
QoL. In fact, even after adjusting with EQ-5D index, 41 (14.6%) patients retained full 
maximum days. 




 Total % 
Potential days 101,787  
Days lost to   
   Death 12,354 12.14 
   Hospitalisation* 3,715 3.65 
   Impaired QoL# 24,867 24.43 
   Diuretic adjustment 740 0.73 
Total days lost 41,676 40.94 
Patient Journey 60,111 59.06 
*All hospitalisation (unplanned and elective) for all causes; #Using Australian based 
mean EQ-5D indices. 
5.6.3 African American Heart Failure Trial composite outcome 
The A-HeFT composite score consisted of weighted values for death from any 
causes, a first adjudicated HF hospitalization, and change in the QoL. In this study 
110 (39.5%) had overall A-HeFT positive score, 49 patients (17.5%) with overall 
score of 0 and 119 (42.8%) with negative score. The mean was -0.5 (sd=2.1; median 
=0.0; IQR =3.0). 23.7% (n=66) patients achieved a maximum score of 2, a highest 
possible score for A-HeFT composite. This score can only be achieved in the 
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absence of death and HF hospitalisation, and a marked improvement in QoL scores 
(ie. Change of 10 or more points in MLWHFQ). Three (1.1%) patients scored -6, a 
lowest possible score which can only be achieved with markedly worsening of QoL, 
first HF hospitalisation and death (Table 5.6).  
Table 5.6.  Distribution of African American Heart Failure Trial composite score (n=278*) 
A-HeFT score n (%) 
-6 3 (1.1) 
-4 31 (11.2) 
-3 31 (11.2) 
-2 34 (12.2) 
-1 20 (7.2) 
0 49 (17.6) 
1 44 (15.8) 
2 66 (23.7) 
Total 278 (100.0) 
Mean ±SD  
 
-0.5 ± 2.1 
Median ± IQR  0.0 ± 3.0 
*2 patients were excluded from the analysis 
With A-HeFT composite scores, indication of improvement as expressed in positive 
overall scores can only be achieved with an increase in QoL scores. However 
indication of deterioration (negative score) is measured with death, first 
hospitalisation and worsening in QoL. In examining the impact of each component 
of the composite for worsening condition (ie. only negative A-HeFT score), 45.4% 




Table 5.7. Derivation of weights assigned to African American Heart Failure Trial composite response (n=278) 
Composite 
scoring system 
Criteria Score n (%) Weight 
assigned to 
the score 
(Score X n) 
% 
Death Death from any cause anytime during the 12 month 
followup 
 
-3 57 (20.4) -171 45.4 
Hospitalisation A first hospitalisation for heart failure -1 111 (39.6) -111 29.4 
Change in QoL at 
12 months 
Increased by 10 or more units = markedly worsened -2 44 (15.7) -88 25.2 
 Increased by 5 to 9 units = worsened -1 7 (2.5) -7  
 
 Changed by -4 to 4 units = no change 0 103 (36.8) 0  
 
 Reduction by -5 to -9 units = improvement 1 20 (7.1) 20  
 Reduction by -10 or more units = markedly improvement 2 104 (37.1) 208  
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Despite all three composite outcomes incorporating mortality, hospitalisation and 
QoL, the contribution of each individual component to the final outcomes were 
different. Using the data from WHICH(?) trial [8], the component with the most 
influence for the Packer’s ordinal composite score [6] was hospitalization (67.7%) 
while in Patient Journey [5] it was QoL (61.5%) and for A-HeFT composite score [33] 
it was mortality (45.4%) (Table 5.8).  
Table 5.8. Percentage contribution of each components to Packer’s score, Patient Journey 
and African American Heart Failure Trial score for deteriorating conditions (n=280) 
Components 
Percentage (%) contribution to deteriorating condition 
Packer’s score Patient Journey A-HeFT 
Death 11.0 29.6 45.4 
Hospitalisation 67.7 8.9 29.4 
QoL 21.3 61.5 25.2 
5.6.4 Application of Composite outcomes to compare Clinical based intervention and 
Home based intervention 
With the significance level set at 0.05, a two way chi-square showed a non-
significant association between Packer’s score and the study assignment (HBI or 
CBI) (χ2(2, N=280) =1.39, p=0.50). The frequencies are shown in Table 5.9. 
Similarly, there was no statistical significant difference between the study 
assignment and A-HeFT score (p=0.30) nor between study assignment and Patient 
Journey (p=0.21). Only component of Patient Journey marginally significant 
between HBI and CBI was days lost due to hospitalisation (p=0.04). However 
considering multiple testings were carried out on Patient Journey and its 
components, this result is not significant when compared against adjusted alpha 
level (adjusted alpha=0.008). Descriptive statistics for Patient Journey and its 
components are reported in Table 5.10. A-HeFT scores and its descriptive statistics 
of HBI and CBI groups are reported in Table 5.11 
 To assess the group difference of the component all-cause mortality and 
hospitalisation for the Packer’s score and A-HeFT score hazard ratio were 
examined. They were all not significant (Table 5.12). 
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Table 5.9. Frequency of Packer’s score by chronic heart failure management group (n=280) 
Group 
Packer’s score  
Worse Same Better Total 
HBI 79 (55.2) 16 (11.2) 48 (33.6) 143  
CBI 85 (62.0) 14 (10.2) 38 (27.7) 137 
Total 164 (58.6) 30 (10.7) 86 (30.7) 280 
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Table 5.11. Descriptive Statistics of African American Heart Failure Trial score for study 
assignments (n=280) 
Groups n M Mdn SD IQR 
HBI 143 -0.37 0.0 2.03 3.00 
CBI 135 -0.70 0.0 2.24 5.00 
Total 278 -0.53 0.0 2.14 3.00 
Table 5.12. Clinical events* during one year follow-up (n=280) 







 n(%)   
All cause death 27 (18.9) 30 (21.9) 0.84 (0.50 – 1.41) 0.51 
HF hospitalisation  53 (37.1) 58 (42.3) 0.86 (0.60 – 1.25) 0.44 
Death or HF hosp. 62 (43.6) 67 (48.9) 0.87 (0.62 - 1.23) 0.43 
*Events are not mutually exclusive; # Hazard ratios are based on Cox proportional-
hazards regression models applied to an analysis of the time to the first event. 
5.6.5 Relationship between Packer’s composite, Patient Journey and African American 
Heart Failure Trial 
The correlation coefficients demonstrate substantial associations amongst all three 
composite outcomes. The correlation between Packer’s score and Patient Journey 
was moderate (γ =0.49). Examining Patient Journey for each category of Packer 
composite score demonstrated good agreement between Packer’s score and 
Patient Journey days. Patients in worse category in Packer’s score lost 50.9% of all 
potential days to mortality, hospitalisation and impaired QoL, while in same 
category, 23.4% of the days were lost and in better, 28.2% (Table 5.13). This 
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substantial difference in days lost in worse category to the same and better is 
driven by days lost due to mortality and hospitalisation. In the worse category, 
20.7% of days were lost due to death while no days were lost to mortality in the 
same and better categories. Similarly in the worse category (5.1%) larger proportion 
of days were lost to hospitalisation than in the same category (1.5%) or in the 
better category (1.6%). The pattern and magnitude of proportion of days lost was 
similar between same and better categories of Packer’s score (Table 5.13).  
Table 5.13. Patient Journey by Packer’s score (n=280) 
 Packer’s score 
 Patient Journey Worse (n=164) Same (n=30) Better (n=86) 
  Total % Total %  Total %  






       Days lost to 
      
     Death 12,354 20.7% 
                       
-    0.00% 0 0.0% 
     Hospitalisation 3,056 5.1% 166 1.5% 493 1.6% 
     Impaired QoL 14,497 24.3% 2,347 21.4% 8,023 25.7% 
     Diuretic adjustment 403 0.7% 53 0.5% 284 0.9% 
Total days lost 30,310 50.9% 2,566 23.4% 8,800 28.2% 
       Patient Journey 29,289 49.1% 8,384 76.6% 22,438 71.8% 
A similar pattern emerged between Patient Journey and A-HeFT score. The 
correlation between Patient Journey and A-HeFT score was moderate (ρ = 0.54) 
(see Figure 5.1). For lower scores of A-HeFT scores (from -6 to -3) more than 50% of 
days were lost to mortality, hospitalisation and impaired QoL driven mainly by days 
lost to mortality (Table 5.14). In fact for A-HeFT scores from -6 to -3, the cause of 
largest proportion of days lost was mortality followed by impaired QoL. However 
for A-HeFT scores between -2 and 2, the greatest days lost was from impaired QoL 































Table 5.14. Patient Journey by African American Heart Failure Trial composite 




















Potential days  1,095  -  11,315  11,278   12,308   7,263.00   17,871   15,967   23,960  
          
Days lost to          
     Death  269  (24.6) -  7,003 (61.9)  4,642 (41.2)  392 (3.2)  48 (0.7) - - - 
     Hospitalisation  81 (7.4)  -  676 (6.0)  732 (6.5)   324 (2.6)  446 (6.1)  338 (1.9)  782 (4.9)  281 (1.2)  
     Impaired QoL  246 (22.4) -  1,181 (10.4)  2,387 (21.2)  3,885 (31.6)  2,057 (28.3)  4,424 (24.8)  5,0807 (31.9)   5,438 (22.7)  
     Diuretic adjustment  -    - -  70 (0.6)  131 (1.1)   75 (1.0)   106 (0.6)   97 (0.6)   236 (1.0) 
Total days lost  596 (54.4)  -  8,860 (78.3)   7,831 (69.4)  4,732 (38.4)  2,627 (36.2)  4,869 (27.2)   5,966 (37.4)   5,956 (24.9)  
          




The overall correlation between Packer’s and A-HeFT score was γ =0.86. A Krusal-
Wallis nonparametric test was used to analyse the A-HeFT score for the Packer’s 
scores. The result was highly significant (χ2 (2, N=278) = 156.967, p<001). Three 
post hoc comparisons between pairwise means were conducted using the Mann-
Whitney test, and an adjusted alpha of 0.017. All three tests were all statistically 
significant, where a lowest median score was achieved in worse category, followed 
by same and then the highest in the better category. Descriptive statistics are 
shown in Table 5.15 (see Figure 5.2). 
Table 5.15. Descriptive statistics on African American Heart Failure Trial score for Packer’s 
composite (n=278) 
Packer score n M Mdn SD Range 
Worse 162 -1.77 -2.00 1.89 8 
Same 30 0.00 0.00 0.00 0 
Better 86 1.62 2.00 0.71 2 
Total 278 -0.53 0.00 2.14 8 
 





















Quantifying health in terms of death and disease rates in chronic condition is seen 
to be increasingly inadequate. Developing a core outcome set including QoL 
oriented PROs alongside mortality and hospitalisation would enable evidence 
synthesis across different studies. As a consequence of the shortfall of each 
unidimensional measurement, a composite outcome aggregating multidimensional 
concepts has emerged to provide a multifaceted profile that cannot be represented 
by any individual outcome alone. This study compared Packer’s score, Patient 
Journey and A-HeFT score, where three composite outcomes that incorporated 
mortality, hospitalisation and QoL.  It also examined the methodological issues in 
derivation of each composite outcome to gain insights into the relationship among 
three composite outcomes. As there is no established gold standard for assessing 
the absolute effect on any outcome measure, it would be premature to assess 
which composite outcome is the ‘best’. Most likely the ‘best’ measure would be the 
one that addresses the research question most appropriately.   
Interestingly, all three composite outcomes provided similar result for the 
comparison between HBI and CBI study. This may be due to synergies in the 
outcomes mortality, hospitalization and QoL. 
5.7.1 Packer’s score 
The Packer’s score is perhaps the most well-known and widely used composite 
outcome in CHF [34]. Deriving this composite requires two stages. First, it involves 
‘time to event’ methods, where patients are monitored until the death or first HF 
hospitalisation within the follow-up period. Second, those who are alive at follow-
up and have not been hospitalised for HF will be assess for a change in their QoL 
score and/or NYHA functional class. Depending on the magnitude of the change in 
QoL/NYHA, patients will be classified into either ‘worse’, ‘same’ or ‘improved’ 
group. Consequently, this composite outcome provides only a qualitative 
assessment. 
In the first stage of the derivation method, death and HF hospitalisation are 
considered to have the same weight despite the fact that patients may view these 
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components of the composite very differently. As HF hospitalisation occurs more 
frequently than death, the patient’s final outcome may be determined more 
frequently by HF hospitalisation rather than less frequent but more serious 
outcome, mortality. As demonstrated in this study (Table 5.8) this inordinate weight 
assigned to HF hospitalisation would have the potential to create a problem in 
interpreting the result due to the variation in clinical importance [16]. A patient 
who has a single, short, early admission is placed into ‘worse’ category similarly to 
death, when in fact a short HF hospitalisation may reflect early detection of 
problems and hence a good care rather than an adverse outcome. In this study 
41.4% of patients who were hospitalised during 12 month follow-up also reported 
improvement in their QoL. This implies that hospitalisation for HF does not 
necessarily indicate worse outcomes. 
The information used on the component HF hospitalisation is an indicator variable. 
Hence, information on duration and severity of the HF hospitalisation are not 
captured in this composite outcome. Furthermore, this component only considers 
the first HF hospitalisation, disregarding the subsequent HF hospitalisation despite 
36% of patients had multiple hospitalisations due to worsening HF in this study.  
In the second stage of categorisation, assessing changes in NYHA functional class 
and patient assessment during the follow-up period would only be on patients who 
have not been censored due to death or HF hospitalisation. Consequently, the 
analysis of QoL component would be per protocol rather than on intention to treat 
basis. In addition, mortality and hospitalisation is prioritised above QoL component 
and the changes in QoL component would only come into effect to those who have 
survived and not been hospitalised. Hence it is not surprising the Packer’s score is 
most influenced by first hospitalisation rather than mortality or QoL components 
(Table 5.8).  
One of the strengths of the Packer’s score is that it considers the change in QoL 
from both the patient and clinician perspective with equal weight. However, this 
may potentially create a problem when they differ significantly or contradict each 
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other. Just over 50% of agreement was observed between NYHA functional class 
and the patient’s assessment in this study. 
5.7.2 Patient Journey 
Patient journey is different to other composites. QoL scores are assessed on an 
absolute scale rather than as a change from baseline. This has the advantage of 
avoiding the problem of recall bias of symptoms/QoL and of the variability that may 
result due to temporary deterioration. However, to increase internal validity of the 
result, QoL scores at baseline in comparison groups need to be similar. In addition, 
the duration of the follow-up need to be comparable amongst comparison groups, 
especially as the final outcome is expressed as total days for each group rather than 
the mean days. 
Patient Journey usually leads to a highly skewed outcome with many patients at a 
near perfect score. In this study, 71 (25.4%) patients were not hospitalised nor died. 
Even after adjusting with EQ-5D index, 41 (14.6%) patients achieved the maximum 
score. Such skewed data are usually difficult to analyse and less powerful 
nonparametric methods would need to be utilised [11].  
In the metric of the Patient’s Journey, the DAOH are usually adjusted by arbitrary 
weights assigned to five point patient QoL score. Given days lost due to QoL has 
potentially the largest impact on Patient Journey (Table 5.8), these weights can 
have greatest influence on the final outcome. Yet, these weights have not been 
validated [35] and in general, there would be disagreement among clinicians and 
patients about the value and the appropriateness of these weights. In present 
study, EQ-5D index was used for Patient Journey. This may provide more sensitive 
and appropriate weight [30]. In addition Patient Journey focuses on the 
deteriorating state. Any improvement cannot be measured with this composite 
outcome.  
5.7.3 African American Heart Failure Trial composite score 
A major strength of an A-HeFT composite outcome is that patients can contribute 
to all components of the outcome. However in the computation of the score only 
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first HF hospitalisation is captured. The explanation provided is that this would 
avoid multiple HF hospitalisations to add up to a score equivalent to death [31]. 
Hence in this composite outcome, death is considered as the worst outcome and, 
death at any time from any cause receives the worst score. 
One of the interesting feature of the A-HeFT composite outcome is the change in 
QoL is given a wide range of weights, and it can potentially have bigger influence on 
the final outcome than hospitalisation. Having a big change in QoL is considered 
twice as important as first HF hospitalisation. However, when only negative A-HeFT 
scores (worsening condition) were examined, hospitalisation had marginally larger 
impact on the final outcome than QoL in this present study. Major disadvantage to 
A-HeFT score is that the weight assigned to each component have not been 
validated. Consequently, the magnitude of clinically meaningful difference would 
be difficult to achieve. 
Although there was a moderate correlation between the Packer’s score and the 
Patient Journey, and also between the A-HeFT score and Patient Journey in this 
analysis, there was no clear pattern when patients have improved or remained the 
same. In all three composite outcomes the focus was on deteriorating clinical 
status. Hence their use is limited to measuring worsening clinical status and not of 
improvement. This is especially the case in Patient Journey which only considers 
deteriorating state. Interestingly, in Packer’s score and A-HeFT composite, only 
component that would determine patients as improved or same is QoL component 
albeit they must be alive and have not been hospitalised. 
The only pair of scores with high correlations is between the A-HeFT and Packer’s 
score with some pattern emerging. This may be due to using same outcome 
measures, namely all-cause mortality and first HF hospitalisation as an indicator 
variable and MLWHFQ assessed in similar way, albeit with different weight and 
classification. 
In planning a study, one of the most important decisions that investigators make is 
the choice of the outcome. Besides aiming to include outcomes that are important 
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to patients, providers and health care system, they need to consider the feasibility 
of measuring them and the efficacy of the intervention. Hence in choosing the 
composite outcomes, understanding the value system of the composite will enable 
potential users to choose appropriately. In this study, the hospitalization 
component was the most influential in determining deteriorating condition in 
Packer’s ordinal composite score[6] while QoL component was for Patient 
Journey[5] and mortality in A-HeFT [34] . This information will aid in the 
interpretation of these composite endpoints as well as provide a rationale for the 
choice of the composite outcomes. 
5.7.4 Limitation 
The analysis in present study is a secondary data analysis which is an important 
limitation. Although each of the three composite outcomes Packer’s score, Patient 
Journey and A-HeFT score, use three similar components (mortality, hospitalisation 
and QoL), there is no validation study to ensure they measure same concepts, nor 
to compare against a gold standard for assessing the totality of the interventions. 
This study is inherently limited by the fact that the patient global assessment was 
not available to be used in calculation of Packer’s score or Patient Journey. 
Consequently the results of Packer’s score and Patient Journey in this study are 
estimates of these composite outcomes. However, using the MLWHFQ instead of 
the patient global assessment for Packer’s score may have provided a more 
detailed description of emotional and physical aspects of QoL than the one-item 
QoL score from patient’s global assessment [36]. Similarly in calculation of Patient 
Journey, EQ-5D was used. Given EQ-5D provide better utility value than restricted 
range of weights that can be applied to patient QoL score with a five point scale 
(25), the result may provide better reflection of the patient experience. 
The derivation of composite outcomes and the examination was limited to one 
study [8]. This may limit the generalizability of the findings. However the aim of the 
study was to obtain a better understanding of issues in composite outcome 
assessment and not to assess validity of these composite outcomes. In addition, as 
there is no gold standard for assessing the totality of the intervention or an 
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independent marker of outcomes, the assessment of validity would be rather 
controversial. 
5.8 Chapter Summary 
There is a widespread interest in using the composite outcome as a primary 
outcome in clinical trials to avoid multiplicity issues and pragmatically for reducing 
sample size. However, trials with a composite primary outcome can be complex and 
raise challenging issues in group comparisons and making recommendations for 
clinical practice. This chapter has examined the structural elements of composite 
outcomes consisting of patient centred outcomes mortality, hospitalisation and QoL 
in a well-controlled clinical trial. Although, each of the composite outcome has a 
varying degree of assigning ‘weights’ to each component, there was a considerable 
agreement amongst these composite outcomes when estimating deteriorating 
condition but not when estimating improvements. Appreciating methodological 
issues in the derivation and interpretation of composite outcomes is important in 
advancing the science of outcome measurement. This analysis emphasises the 
importance of achieving consensus in the weighting and calculation of items in 
measures of composite outcomes to allow comparison of results across clinical 
trials. 
The following chapter provides a discussion of the findings from the previous 
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Incorporating the perspective of patients in clinical trials has been identified as an 
international priority [1]. This thesis has sought to address the vexed issue of 
including the perspective of patients in the metrics of health care policy, clinical 
practice and research.  Although patient centred care is commonly espoused as a 
core value in contemporary health care systems, shifting from rhetoric to reality is 
more challenging [2].  
Beyond the fundamental approach of moving towards partnerships in care and 
shifting from paternalism we need robust, reliable and valid measures of health 
outcomes that are important to the patients [3].  The main objective of this thesis 
has been to investigate outcome measures in chronic conditions that encapsulate 
issues important to patients and how these wishes are translated into policy and 
practice.  CHF has been used as an exemplar to provide the framework of a 
comprehensive evaluation model.  These data have relevance and salience to many 
other chronic conditions. 
The framework used in this thesis has sought to include the perspectives of an 
organisation, providers and consumers. This has been developed with a key 
consideration of incorporating PROs that are meaningful and relevant to patients, 
their families, clinicians and policy makers for a given population or service. The aim 
for this PhD project was to address this issue through conducting a series of studies. 
Specifically this study sought to:  
 Examine patient reported outcomes in clinical management and in clinical 
research (Chapters 2 and 3). 
 Investigate patient important outcomes, their utility, relevance and 
acceptability  amongst patients, clinicians, researchers and administrators 
(Chapter 4) 
 Test composite outcomes model that integrate patient important outcomes 
in clinical trials research (Chapter 5). 
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This chapter will summarise the findings of each of the aims and identify 
implications for the policy, practice and research. Finally the chapter will conclude 
by addressing both the limitations and the implications of the findings of this thesis. 
6.2 Importance of patient perspectives 
For a syndrome such as CHF which is chronic, incurable with debilitating and 
distressing symptoms, it is critical that clinical and therapeutic decisions include the 
patient’s own perspective [3] as well as considering the weight of evidence for a 
therapeutic approach and the assessment of the clinician. Undoubtedly, traditional 
outcome measures, such as mortality and hospitalisation, remain important in CHF 
decision making [4]. However, there has been an increased recognition that PROs 
provide the important additional information in assessing the overall burden of CHF 
and effectiveness of interventions [5].  
Despite the growing recognition, the uptake of PROs in clinical practice [6] has been 
slow and there is a limited evidence of policy decision informed by PROs. With the 
advent of patient centred care defined as “care that is respectful of and responsive 
to individual patient preferences, needs, and values and ensures that patient values 
guide all clinical decisions” [7, p3], choosing outcome measures that are meaningful 
to patients have become critical. Undoubtedly, for many patients, outcomes such 
as mortality and hospitalisation would play a central role and override any 
consideration for other outcomes. However there is evidence to suggest that in 
more severely ill patients with distressing and in times disabling symptoms, an 
improvement in their QoL or symptom relief are more important [8]. Consequently, 
examining PROs in conjunction to mortality and hospitalisation [9] need to be 
considered.  
Given the indisputable importance of traditional biomedical outcome measures, 
particularly mortality and morbidity/hospitalisation in CHF, this thesis has explored 
the importance of PROs in CHF especially its role in clinical management and in 
policy decisions. Furthermore, PIO, namely mortality, hospitalisation and PROs 
were examined for relevance, utility and acceptability in patients, health care 
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professionals and others making decisions and found they were indeed germane 
and critical.  
The implication of this observation is that the combined results from this core 
outcomes set (mortality, hospitalisation and PROs such as QoL) will communicate 
clear and simple information that have the same meaning to all key stakeholders 
and has the important implication for policy, practice and research. This thesis then 
proceeded to test the combined result from the core outcomes set into a single 
composite outcome models already in use in CHF clinical trials. The consequence of 
using a composite outcome is a “net” result that will further facilitate comparability 
and interpretability of core outcomes set that are patient centred, but also 
meaningful at both policy and practice level.   
6.3 Patient Reported Outcomes in clinical management and in clinical 
research 
Epidemiological transitions from infectious to chronic conditions and evolving 
treatment paradigms challenges traditional metrics of morbidity and mortality and 
underscores the importance of assessing PROs, such as QoL [10]. 
While the number of clinical trials incorporating PROs either as a primary or 
secondary outcome has been growing exponentially over the last decades, there is 
an evidence to suggest these outcomes are underutilised in clinical setting [11]. The 
reasons may lie in the difference in data collection, analysis and reporting in PROs 
between clinical trials and clinical management. In clinical trials PROs information is 
collected by research personnel and patients must agree to provide the information 
to be on protocol. Furthermore, information gathered is fed back to the providers 
to monitor the progress and treatment decision. In clinical management however, 
the barriers at provider and system level could prevent collecting and using PROs to 
derive full benefits. At provider level, barriers would be a lack of competence 
amongst clinicians in making sense of the result [12] and scepticism of PROs 
relevance in patient care [13]. At the system level, there would be barriers such as 
lack of resources to facilitate collection and dissemination of PROs information as 
well as the will to incorporate PROs information into clinical workflow. All of these 
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may be due to lack of methodological and reporting rigour of PROs in clinical trials, 
resulting in ignorance of PROs meaning and its capability. 
To explore these issues further, the methodological and reporting rigor of HRQoL 
oriented PRO measures in RCTs of pharmacological therapy in CHF were assessed 
[14]. This study found that despite exponential use of HRQoL in CHF trials over the 
last decade, the reporting was found to be highly variable. Undoubtedly this may 
have raised concern among clinicians, regulators and even researchers about the 
meaning, technical quality, interpretability and decision relevance of the HRQoL 
oriented PROs [15], leading to slow implementation of PROs in clinical practice. 
Additional to ensuring PRO measures are valid, reliable, responsive to change, 
clearly interpretable and relevant to decision makers, there is an urgent need to 
improve the methodological and reporting quality of HRQoL measure in clinical 
research. This study has proposed a standardized method for measuring and 
reporting HRQoL measures in CHF clinical trials to aid in the interpretation and 
application of findings in clinical practice. 
Traditional biomedical outcome measures, particularly mortality and 
morbidity/hospitalisation remain indisputably important in policy decision. 
However the importance of PROs has not been considered in the policy arena. 
Various measures of PROs in CHF that would inform policy decision were explored 
and summarised, and issues such as measurement and utility in the context of 
policy decision making were discussed. Using the Innovative Care for Chronic 
Conditions model [16], a review focusing on developing a metric that incorporates 
PROs in policy planning, implementation and evaluation were extensively 
examined. This study concluded that effective policy and planning of health services 
require understanding of the CHF burden and the treatment effectiveness at an 
individual level that focuses on PROs [17]. 
6.4 Beyond PROs to PIOs  
In order to influence policy and practice, the chosen outcomes need to be relevant 
and important to key stakeholders including patients, health care providers and 
others making decisions about health care. The process of selecting outcome can be 
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complex as selecting inappropriate outcomes may compromise the utility of the 
information. By placing the patient at the centre, the outcomes deemed important 
to patients were investigated for their utility and significance to providers and 
health care system. Mortality, hospitalisation and PRO were selected as being 
relevant and important to all key stakeholders.  These outcomes were proposed as 
a core outcomes set which could potentially provide a comprehensive, comparable, 
meaningful and accurate assessment to patient, providers and health care system. 
6.5 Test composite outcomes that combine patient important outcomes in 
clinical trials research 
A number of composite outcome measures have been developed to capture the 
perspective of the patient, clinician as well as including objective measures of 
health. Using the data from the WHICH? trial, this study compared the performance 
of the three composite outcomes already in use in CHF clinical trials. The final 
results of the comparison between the study assignments were consistent. There 
are moderate agreements amongst the composite outcomes despite the primary 
driver of each composite outcome for the worsening condition was different. 
Despite this, achieving consensus in the weighting and calculation of items in 
measures of composite outcomes are critical.  
6.6 Implications for health policy 
At policy level, it is important to balance the societal benefits and expenditure. 
There is a need to understand the relative benefits of the various treatment options 
for CHF in terms of economic, clinical and QoL outcomes. Outcome measures that 
currently inform benefits and burdens of CHF at the policy level are CHF incidence, 
mortality and economic cost [18]. Economic cost of CHF need to be considered both 
in terms of direct or total costs. Some examples of direct costs include cost of 
hospitalisation as well as medication. Subsequently in a core outcomes set, 
hospitalisation can be used as a surrogate marker of resource use and may be 
appropriate in cost-effectiveness evaluations. 
Undeniably, there is clearer information of CHF survival to influence policy than 
information on issues related to suffering caused by CHF [19]. There is a need to 
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supplement traditional clinical outcomes such as mortality and hospitalisation with 
PROs. However PROs are not routinely collected and analysed at the system level. 
This means PROs such as HRQoL or patient needs and satisfaction with care have 
had limited influence at this level. 
Increasingly, the importance of this issue in driving health care policy is recognised 
by groups such as PCORI in the US [20] and PROMs in the UK [21]. As illustrated in 
this thesis these initiatives to cast the light on PROs is largely dependent on the 
psychometric properties of instruments as well as the vehicle and the mode in 
which these are delivered.  
There is a growing recognition that insufficient attention has been paid to the 
selection of the outcomes to measure in clinical trials and clinical audit. Outcomes 
need to be relevant to patients, clinicians, purchasers and policy-makers if the 
findings of research are to influence practice and future research.  
6.7 Implications for practice 
In clinical practice, health care providers aim to increase survival, prevent future 
morbidity and to improve patients’ QoL. Consequently outcome measures are 
needed to monitor the result of care and to supplement any information to 
improve patient care. Outcomes such as adverse events, mortality and morbidity 
and/or CHF rehospitalisation are considered to be important outcome measure in 
practice setting. In recent times, however there has been a growing awareness of 
the need to take account of patients’ perspective, especially in the view of wide 
discrepancies between clinicians’ and patients’ assessment of treatment 
effectiveness and symptoms [22]. Incorporating patients’ perspective in the form of 
PROs means an essential element of patient centred care [23] is being practiced. 
Indeed, there has been a call to include PROs in routine clinical practice [3].  
Individual PROs data can potentially alert providers to the problems they may not 
been able to be detect otherwise.  These measures also provide a way to monitor 
treatment benefits/risks leading to better patient care. This is also a potentially 
useful strategy in increasing individuals’ participation in their own treatment and 
also in health care decision making. Patient adherence is a major impediment to the 
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effectiveness of therapies. Increased patient satisfaction with a treatment has been 
shown to be related to adherence [24]. Accordingly, evaluating satisfaction with 
treatment may assist health care providers in understanding the issues influencing 
treatment adherence and may help identify aspects of the management plan that 
require improvement to enhance long term treatment outcome [25].  
Increasingly CHF patients are being cared for by multidisciplinary teams in which 
health care providers from different professions work together [26]. PROs facilitate 
communication amongst the team by providing a common language amongst 
professions from different background [11] to coordinate optimal patient care.  
Provider centred outcome measures should ideally require minimal additional 
resources and minimal disruption to the delivery of care. Furthermore they should 
be clinically useful and acceptable to patients [27]. 
Beyond clinical research, obtaining the perspective of patients is critical in everyday 
encounters. Ensuring PROs are valid, reliable and easily completed should be an 
important focus of health care professionals. Technological innovations, such as 
using tablets, shows some promise as well as instruments such as the Dartmouth 
COOP/WONGA (World Organization of National Colleges, Academies, and Academic 
Associations of General Practices/Family Physicians) charts[28] which strive to 
minimise the challenges of literacy and cognition [29]. It is important that patients, 
their carers and health care professionals are aware of the value of PROs in 
improving care. Obtaining consensus on standardised measures across health care 
settings will ensure generation of normative data and increase the skills and 
expertise of clinicians for incorporating these data in clinical assessment, planning 
and treatment allocation [30]. 
6.8 Implications for research 
The selection of an outcome is arguably one of the most important steps in clinical 
trials. CHF clinical trials have traditionally considered relatively objective clinical 
outcome measures such as mortality, morbidity/hospitalisation or even biological 
response to treatment. In recent decades, the number of CHF clinical trials 
incorporating PROs especially HRQoL assessment as a secondary and sometimes as 
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primary endpoint have increased exponentially [31] [32, 33].  It is recognition that 
PROs generally compliment other outcomes in the study [34].  
The establishment of the Patient-Reported Outcomes Measurement Information 
System (PROMIS) and the regulatory bodies such as the FDA in the US requesting 
PROs data for the drug approval decisions [35] have consolidated the role of PROs 
as an important endpoint in clinical trials. However, there is a limited scientific 
rigour in reporting of PROs such as HRQoL in CHF studies as reported in this thesis. 
In CHF clinical trials however, where clinical outcomes such as mortality or 
morbidity/rehospitalisation may be the primary outcome, methodological issues in 
PROs assessment may be inadequately addressed. These issues could be resolved 
by developing a core outcomes set that include PROs. This may accelerate the 
science of PROs further in data collection, appropriate timing of assessment, 
adequate statistical analysis as well as in interpretation of the results [36]. In 
addition, issues of multiplicity and heterogeneity of PROs tools, which has 
hampered synthesis and summaries of the effect, would be addressed by specifying 
the standardized PROs measure for all CHF trials.  
Development and application of these core outcome set will also address 
difficulties arising in systematic reviews as a result of heterogeneity in outcome 
measurements [37]. Standardization of outcomes is needed to combine data from 
different studies to allow evidence synthesis and to compare data sets. Inconsistent 
choice of outcome measures means that many meta-analyses are unable to include 
data from all the relevant studies. For example, the five most accessed Cochrane 
reviews in 2009, together with the top cited review in that year, all described 
inconsistencies in the outcomes reported in eligible trials [20]. A call for the 
standardization of outcomes and nomenclature is a regular conclusion of 
systematic reviews [21]. In addition,  outcome reporting bias, defined as the bias 
arising from selecting outcomes for publication based on the results, that affects 
many randomized trials [38] and ‘is an under-recognized problem that affects the 
conclusions in a substantial proportion of Cochrane reviews’ [39] would be 
addressed with the core outcomes set.  
 
158 
6.9 Study Limitation 
It is notable that in developing PIOs, we had not directly asked patients what they 
considered to be the most relevant outcomes. It seems logical that their 
involvement would help determine the most appropriate outcomes to measure.  
However, we did derive data from the reviews of the outcomes in heart failure 
trajectory.  Generating consumer views on findings of this study will be an 
important first step in moving towards a shared set of outcome measures.  
As mentioned in Chapter Five, a development of core outcome sets require more 
than agreeing on the type and number of discrete outcome measure. There needs 
to be an agreement on how each of these outcomes (mortality, hospitalisation and 
QoL oriented PROs) is to be defined, measured and interpreted. 
6.10 Conclusion 
This thesis has identified that a triad of measurement- mortality, hospitalisation 
and QoL are likely to be of significant to the perspective of patient, provider and 
health care system. By utilising the same core outcomes important to all 
participants of health in clinical policy, practice and research, information would be 
interpretable by all stakeholders of CHF care and findings in one stakeholder may 
inform other stakeholders. This would be simplified further by using a composite 
outcome. However, testing the performance of three composite outcomes has 
emphasised the importance of achieving consensus in the weighting and the 
methodology in calculating each component in measures of composite outcomes. 
Advancing this science will require the combination of (i) expert knowledge of the 
illness trajectory; (ii) appraisal of evidence based interventions; (iii) the perspective 
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Appendix 3 Search Strategy for Patient Important Outcome (Chapter 4) 
1 exp heart failure/ 
2 chronic heart failure.mp. 
3 chronic cardiac failure.mp. 
4 "outcome assessment (health care)".mp. or "Outcome Assessment 
(Health Care)"/ 
5 outcomes assessment.mp. 
6 assessment, outcomes.mp. 
7 or/1-3 
8 endpoint$ assessment.mp. 
9 assessment, endpoint$.mp. 
10 4 or 5 or 6 or 8 or 9 
11 7 and 10 
12 limit 11 to (english language and (comment or editorial or "review")) 
13 outcome$ classification.mp. 
14 classification, outcome$.mp. 
15 endpont$ classification.mp. 
16 classification, endpoint$.mp. 
17 13 or 14 
18 7 and 17 
19 Patient Satisfaction/ or "Quality of Life"/ or patient reported 
outcome$.mp. 
20 7 and 19 
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21 limit 20 to (english language and (comment or editorial or "review")) 
22 health care outcome$.mp. [mp=protocol supplementary concept, rare 
disease supplementary concept, title, original title, abstract, name of 
substance word, subject heading word, unique identifier] 
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